Interparfums

Meeting notice Combined Ordinary and Extraordinary General Meeting of June 24, 2020



Important Notice - Covid-19

In the context of the Covid-19 epidemic and in light of public health measures adopted in France to limit or prohibit public gatherings, the procedures for the organization of and the shareholders' participation in the General Meeting to be held on June 24, 2020 have been modified.

In accordance with the provisions of article 4 of Order No. 2020-321 of March 25, 2020 adopted under the powers granted by French Emergency Law No. 2020-290 of March 23, 2020 to deal with the Covid-19 epidemic, the Combined Ordinary and Extraordinary General Meeting of the Company of June 24, 2020, pursuant to the decision of the Board of Directors, will be held in closed session, in the absence of the physical presence of the shareholders and other persons entitled to attend.

Shareholders may vote by mail or by granting a proxy using the form provided for that purpose and available in the special section of the Company's website www.interparfums-finance.fr for the 2020 Annual General Meeting or electronically through the secure VotAccess voting platform. These henceforth represent the only methods available to shareholders for participating in the meeting held in closed session.

Shareholders are invited to consult on a regular basis the special section for the 2020 Annual General Meeting at of the Company's website www.interparfums-finance.fr

Within the framework of relations between the Company and its shareholders, it is strongly recommended that email be used in priority for the transmission of any requests or documents: relationsactionnaires@interparfums.fr.

Shareholders are informed that, in light of the current restrictions of movement, the Company might not be able to receive communications sent by regular mail at the present time.

Translation disclaimer: This English version has been prepared for the convenience of English speaking readers. It is a translation of the original French Avis de convocation published for the Company's Annual General Meeting. It is intended for general information only and in case of discrepancies the French original shall prevail.

Message from Philippe Benacin Chair-CEO



Dear Shareholder,

Due to the current health crisis, it is not possible to hold the Annual General Meeting of the shareholders under normal conditions.

In compliance with the measures provided by law, the Board of Directors decided to hold the Annual General Meeting on Wednesday, June 24, 2020 at 2:00 p.m. at the Company's registered office in closed session.

While this means that this year you will be unable to physically participate in the Meeting, it will nevertheless be broadcast on the Company's website www.interparfums-finance.fr.

We do however very much hope that you will participate in this Meeting by using the voting form or the VOTACCESS electronic voting platform that we have set up this year to facilitate your participation on a remote basis.

You may also appoint a proxy holder or authorize the Meeting's Chairman to

vote in your name.

The meeting agenda and draft resolutions are provided in this document.

In this context, we will be very attentive to ensuring that your rights are respected and the quality of our exchanges in responding to your written questions.

To submit your questions, please use the procedure for written questions either by mail or, more simply, by email at the email address: assembleeqenerale2020@interparfums.fr.

We also invite you to read through this document which describes the practical procedures for participating in this AGM. Additional information on the AGM can be found at our website: www.interparfums-finance.fr/assembleegenerale.php where you will be able to consult the main relevant documents

We thank you for your loyalty and confidence and take this opportunity to express our hope that you and your loved ones remain safe during this health crisis.

Participation in the Annual General Meeting

Conditions for participation

The Meeting is comprised of all shareholders, regardless of the number of shares owned.

Only shareholders providing proof that their shares are registered in their own name or in the name of the registered intermediary on the second business day prior to the meeting date may participate, i.e. June 22, 2020 at midnight (Paris time):

- in registered share accounts maintained by the Company;
- in bearer share accounts maintained by an authorized intermediary.

Special procedures with respect to attending the General Meeting during the health crisis

In light of the fact that it is exceptionally held in close session, shareholders have the choice of participating in the General Meeting*in one of three manners:


- a) by giving their proxy to a third-party of their choice under the conditions provided for by article L. 225-106 of the French commercial code (proxy holder), it being specified that in this case, the proxy holder is required to vote by mail by virtue of this power;
- b) by sending a proxy to the Company without indicating a proxy holder (granting the proxy to the Chairman);
- c) Vote by mail.

Shareholders may vote by mail or by granting a proxy by using the form provided for that purpose or electronically by using the secure VotAccess voting platform.

These henceforth represent the only methods available to shareholders for participating in the meeting held in closed session.

Participation in the Annual General Meeting: voting using a paper form

If you wish to vote by mail, give your proxy to the Chairman or be represented by a third-party of your choice but prefer to send your voting/proxy form by regular mail, in this case it must be completed as follows:



Obtaining a voting form

The voting/proxy form will be available from the Company's website no later than the twenty first day preceding the Meeting:

www.interparfums-finance.fr

As from the time the meeting is called, bearer shareholders may request to receive this form by writing to:

CIC - Service Assemblées Générales 6 avenue de Provence 75452 Paris Cedex 09

or by email at:

serviceproxy@cic.fr

Requests for forms must be received no later than six days before the date of the Meeting, i.e. until June 18, 2020.

Returning the voting form

The voting/proxy form must be sent back, accompanied for holders of bearer shares by their certificate of attendance (attestation de participation).

This form must be received by CIC - Service Assemblées Générales, either by mail at the following address:

CIC - Service Assemblées Générales 6 avenue de Provence 75452 Paris Cedex 09

or by email at:

serviceproxy@cic.fr

up until the fourth day preceding the date of the General Meeting i.e. no later than June 20, 2020.

Voting by proxy

Proxies granted to a third-party are valid if received by CIC - Service Assemblées Générales, either by mail at the following address:

CIC - Service Assemblées Générales 6 avenue de Provence 75452 Paris Cedex 09

or by email at:

serviceproxy@cic.fr

up until the fourth day preceding the date of the General Meeting i.e. no later than June 20, 2020.

Because proxies are not able to physically to attend Meeting, they must send their instructions for exercising their votes to CIC - Service Assemblées Générales at the following email address:

serviceproxy@cic.fr

by using the voting form, no later than the fourth day preceding the date of the General Meeting **i.e. no later than June 20, 2020**.

Shareholders who have already cast their vote remotely, sent a proxy or attendance certificate may elect to participate in the Meeting in another manner, on condition that their instructions to that effect have been received within a timeframe that is consistent with the rules for each method of participation. In that case, the instructions previously received will be canceled.

Participating in the General Meeting: online voting

- **For registered shareholders**: Holders of registered shares (held in custody-only and managed accounts) wishing to grant a proxy online may do so by using the VotAccess voting platform which can be accessed at the following address: https://www.actionnaire.cmcicms.com

Holders of registered shares maintained in a custody-only account (compte nominatif pur) may do so by logging on using their regular identifiers indicated in their portfolio statement.

Holders of registered shares maintained in a managed account (compte nominatif administré) will receive their identifier and password by mail. Shareholders who no longer possess their identifier and/or password may contact the following number provided for this purpose: +33 1 53 48 80 10

After logging on, the registered shareholder must follow the instructions provided on the screen to access the VotAccess voting platform in order to vote or grant a proxy.

- **For holders of bearer shares**: Holders of bearer shares must determine whether or not their registrar is connected to the VOTACCESS voting platform and, as applicable, if such access is subject to specific terms of use.

If the registrar maintaining the shareholder's securities account is connected to the VOTACCESS voting platform, the shareholder logs on to the web portal of this intermediary using his or her normal access codes. This shareholder then clicks on the icon displayed on the line corresponding to Interparfums shares and follow the instructions provided on-screen to access the VOTACCESS platform in order to vote or grant a proxy.

The VOTACCESS voting platform will be open from June 5 2020 to June 23, 2020, 3:00 p.m., Paris time.

The option of voting online before the General Meeting will cease to be available the day before the Meeting, i.e. **June 23, 2020 at 3:00 p.m., Paris time**, except for the proxies granted to third parties which must be received no later than June 20, 2020.

However, in order to prevent the VOTACCESS voting platform from being overloaded, it is recommended that shareholders do not wait until the day preceding the Meeting in order to vote.

Important notice: new procedure for processing abstentions

The French law No. 2019-744 of July 19, 2019 modified the rules for calculating votes expressed in shareholders' General Meetings: whereas abstentions were previously considered as "no" votes, at the next General Meeting, there will henceforth be excluded from votes expressed and as such not taken into account in the basis for calculating the majority required for adopting resolutions. The mail/proxy voting forms have in consequence been modified so that shareholders can separately express either a "no" vote or an abstention for the different resolutions submitted to the Meeting.

For any information, please contact:

- Contact CM-CIC Titres Service Assemblées, Odile Gruet, Tel.: +33 (0)1 53 48 81 07 Email: serviceproxy@cic.fr
 CIC Service Assemblées Générales
 6 Avenue de Provence
 75009 Paris
- Consult our website: <u>www.interparfums.fr</u>
- Interparfums shareholder services: Monday to Friday, from 9 a.m. to 6 p.m. (Paris time) at the toll-free number for calls within France 0 800 47 47 47 and when calling from outside France + 33 (0)1 53 77 00 99.
- Or write us at: Interparfums,
 Shareholder Relations,
 Karine Marty,
 4 Rond-point des Champs-Élysées,
 75008 Paris
 or by email at relationsactionnaires@interparfums.fr

KEY INFORMATION

Voting by mail Deadline for receiving documents:

Saturday, June 20, 2020 (midnight, Paris time)

Voting by proxy Deadline for receiving documents:

Saturday, June 20, 2020 (midnight, Paris time)

Opening of the VOTACCESS site From June 5, 2020 to June 23, 2020, 3:00 p.m., Paris time



Agenda

Ordinary resolutions

- Approval of the annual financial statements for the period ended December 31, 2019 Approval of non-deductible expenses
- 2. Approval of the consolidated financial statements for the period ended December 31, 2019;
- 3. Appropriation of net income of the period
- 4. Statutory Auditors' special report on regulated agreements and commitments Recognition of the absence of new agreements;
- 5. Reappointment of Mrs. Dominique Cyrot as director;
- 6. Approval of the compensation policy for members of the Board of Directors;
- Approval of the compensation policy for the Chairman-Chief Executive Officer or any other executive officer:
- 8. Approval of the disclosures referred to in I of article L. 225-37-3 of the French commercial code (code de commerce)
- Approval of the fixed, variable or exceptional components of total compensation and benefits of any nature paid in the period ended or granted for the same period to Mr. Philippe Benacin, Chairman-Chief Executive Officer
- 10. Authorization to be granted to the Board of Directors for dealing in own shares within the framework of article L.225-209 of the French commercial code, length of authorization, purposes, procedures, limits.

Extraordinary resolutions

- 11. Authorization to be granted to the Board of Directors to cancel shares purchased in connection with article L.225-209 of the French Commercial Code, duration of the authorization, ceiling;
- 12. Fourteenth resolution Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities (of the company or a group company), and/or securities giving access to ordinary shares (of the Company or a Group company), maintaining shareholders' preferential subscription rights, duration of the delegation of authority, maximum nominal amount of the capital increase, option of offering unsubscribed securities to the public;
- 13. Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities (of the Company or a Group company), and/or securities giving access to ordinary shares (of the Company or a Group company), canceling shareholders' preferential subscription rights by a public offering (with the exception of offers covered by 1 of article L. 411-2 of the French financial and monetary code) and/or in consideration for securities tendered in connection with a public exchange offer, duration of the delegation of authority, maximum nominal amount of the capital increase, issue price, option of limiting the amount of subscriptions or allocating unsubscribed securities;
- 14. Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities (of the Company or a Group company), and/or securities giving access to ordinary shares (of the Company or a Group company), canceling shareholders' preferential subscription rights by an offering covered by 1 of article L. 411-2 of the French financial and monetary code, duration of the delegation of authority, maximum nominal amount of the capital increase, issue price, option of limiting the amount of subscriptions or allocating unsubscribed securities;
- 15. Authorization, in the case of an issue entailing the cancellation of the preferential subscription right, to set, within the limit of 10 % of the share capital per year, the issue price according to the conditions set by the general meeting;
- 16. Authorization to increase the amount of issues;

- 17. Delegation of authority to the Board of Directors to proceed with a capital increase by issuing ordinary shares and/or securities giving access to the share capital within the limit of 10 % of the capital as consideration for in-kind contributions of equity securities giving access to the capital, duration of the delegation of authority;
- 18. Delegation of authority to the Board of Directors to proceed with a capital increase through the issuance of ordinary shares and/or securities giving access to the share capital, suspending shareholders' preferential rights in favor of employees participating in a company savings plan pursuant to the provisions of Articles L. 3332-18 et seq. of the French Labor Code; duration of the delegation of authority, maximum nominal amount of the capital increase, issue price, possibility to grant restricted stock units under article L.3332-21 of the French labor code (code du travail);
- 19. Aggregate limit of ceilings of delegations of authority provided for by the 13th, 14th, 17th and 18th resolutions of this General Meeting;
- 20. Modification of article 14 of the bylaws to provide for recourse to written consultation by the directors;
- 21. Modification of article 14 of the bylaws concerning the use of videoconferencing or telecommunications technology;
- 22. Modification of article 16 of the bylaws concerning the procedures for exercising Executive Management;
- 23. Harmonization of the bylaws;
- 24. Textual references applicable in the case of a change in codification;
- 25. Powers for formalities.

Summary of 2019 results and key figures

Annual operating highlights and key figures

With sales of €484.3 million, up 6.4 % at current exchange rates and 3.6 % at constant exchange rates from 2018, Interparfums continued to grow in 2019. In line with guidance issued at the beginning of 2019 in and reconfirmed in November, this performance in large part reflected the success of Montblanc fragrances in the period.

With sales of more than €140 million, Montblanc fragrances grew nearly 30 % from the previous year. This remarkable performance was the result of an excellent start by the Montblanc Explorer line combined with a solid performance of the brand's founding line, Montblanc Legend.

Jimmy Choo fragrances crossed the €100 million milestone, boosted by flankers rolled out at the end of 2018 and early 2019, but also good initial results by the men's line *Jimmy Choo Urban Hero* launched in the fall

After achieving strong growth for its first three years, Coach fragrances consolidated its market positions with sales of more than €86 million, confirming their potential.

Despite the positive response to the A *Girl in Capri* line rolled out in the spring, Lanvin fragrances registered lower sales in the year while remaining one of the portfolio's solid brands.

Rochas fragrances remained steady with sales of nearly €35 million, reflecting the absence of major launches in the period. The launches of the Byzance and L'Homme Rochas lines at the beginning of 2020 should boost growth in sales over the coming months.

Boucheron fragrances' sales were largely steady with solid performances by the *Quatre* line and its extraordinary Haute Parfumerie fragrance collection.

Van Cleef & Arpels had sales of more than €15 million, up 13 %, based on continuing gains by the *Collection Extraordinaire* line (25 % in 2019) and steady sales for the historic line, *First*.

Finally, Karl Lagerfeld fragrances return to growth, initiated in 2017 with the Les Parfums Matières collection's launch, remains on track.

Sales by region

In € millions and as a % of sales		2018	2019
	North America	140.1	151.7
	South America	35.2	35.0
	Asia	64.1	67.9
	Eastern Europe	40.0	42.6
	Western Europe	91.5	91.6
	France	35.0	36.9
	Middle East	43.2	51.2
	Africa	4.0	5.4
Perfume sales		453.1	482.3
Ro	ochas fashion license revenues	2.2	2.0
Total		455.3	484.3

Driven by the portfolio's 3 top-selling brands, North America registered continuing gains (8 %), particularly in the United States within an overall market for perfumes and cosmetics that grew 2.6 %(1).

In a turbulent economic environment, South America remained resilient with steady sales in the period;

Reflecting the good performances of Montblanc, Jimmy Choo and Coach fragrances, sales in the Middle East grew nearly 20 % in the period.

Benefiting from good performances by Montblanc and Jimmy Choo fragrances respectively, sales in Asia and Eastern Europe grew 6 %;

On a like-for-like sales distribution basis (2), Western Europe achieved growth of nearly 4% linked to the success of the Montblanc Explorer line.

Within an overall market for cosmetics and perfumes which contracted 0.7 %(3), sales in France grew 5 %, here as well driven by the success of the Montblanc Explorer line.


- (1) Source: NPD US.
- (2) Excluding the change in the distribution structure in Italy
- (3) Source: NPD France.



Key consolidated figures


Sales

(in € millions)




Operating profit

(in € millions)




Balance sheet highlights

(in € millions)




Net income

(in € millions)



Net cash

(in € millions)



Consolidated financial highlights

Income statement highlights

Cash position

Trade payables

Group shareholders' equity

Borrowings and financial liabilities

(in € millions)	2016	2017	2018	2019
Sales	365,649	422,047	455,342	484,260
International (%)	90.9 %	91.1 %	92.3 %	92.4 %
Operating profit	49,663	60,025	66,188	73,069
% of sales	13.6 %	14.2 %	14.5 %	15.1 %
Net income	32,438	39,956	47,150	50,633
% of sales	8.9 %	9.5 %	10.4 %	10.5 %
Balance sheet highlights				
(in € millions)			2018	2019
Non-current assets			184.8	188.6
Inventories			100.7	106.5
Trade receivables			91.8	93.7
Current financial assets			59.3	54.0

153.7

444.6

30.5

74.0

151.6

462.8

10.0

63.7

Dividends


Since 1998, the company has adopted a policy of distributing dividends that today represents more than 65 % of consolidated earnings to reward shareholders while at the same time associating them with the Group's expansion. In early May 2019, a dividend of €0.71 per share was paid or a total of €30.3 million.

NB: This information is not part of the management report approved by the Board of Directors on March 2, 2020.

Due to the impact of the above pandemic on the Group's business and the absence of visibility regarding the resumption of activity, the Board of Directors decided not to distribute a dividend for the year ended December 31, 2019. The future dividend policy will depend on a number of factors, and notably results achieved, the Group's financial position as well as market conditions.

Ordinary dividend per share

(In euros, restated for bonus share grants)



2020 outlook

NB: This information is not part of the management report approved by the Board of Directors on March 2, 2020.

In line with expectations, the Group target was met in 2019 with organic growth in sales of €30 million. The Group achieved record performances both for sales and earnings with the operating and net margins attaining high levels. As a result of its very flexible business model and the considerable strength of its balance sheet, despite the current period of market uncertainties, it remains confident in its outlook for the years ahead.

In the context of a global health crisis of unprecedented proportions, even though we have started to see some signs of recovery from several countries in Asia, business in 2020 will nevertheless be significantly affected by the current situation. The progressive resumption of our operations will depend on the gradual reopening of the network of selective perfumeries, particularly in the United States and Europe. In 2020, in addition to reviewing the launch plan timetable for new lines, the Company is taking all possible measures to adjust its expenses to the current situation. The operating cost structure, of which variable costs account for two thirds, will make it possible to effectively adjust expenses to sales. Uncertainties about the development and duration of the current pandemic prevent the Group from evaluating with precision the impact of this crisis on its results. For that reason, in its press release of March 2, 2020, the company withdrew its guidance for the year in progress that was issued with the publication of the 2019 results (See Part 5, "Quarterly financial information and recent disclosures" of the 2019 Registration Document) available at the Company possibility website, www.interparfums-finance.fr].





The New Fragrance
COACH DREAMS Live Yours

Presentation of the Board of Directors

Your Board of Directors has ten members, four of whom are independent:

Philippe Benacin



Chairman-Chief Executive Officer

Date of 1st appointment: January 03, 1989. Date of last reappointment: April 27, 2018.

Philippe Benacin, 61, a graduate of the ESSEC business school and cofounder of the Company with his partner Jean Madar, has served as Chairman-CEO of Interpartums SA since its creation.

Philippe Benacin sets the strategic priorities for the Paris-based Interparfums SA Group and development of the brands of the portfolio: Lanvin, Jimmy Choo, Boucheron, Montblanc, Repetto, Van Cleef & Arpels, Karl Lagerfeld, Paul Smith, S.T. Dupont, Rochas, Coach et Kate Spade.

Current offices:

- President and Vice Chairman of the Board of Interpartums Inc. (United States)

Chairman of the Board of Directors and director of Interparfums Holding

- Managing Partner and President of Interpartums Suisse
- Director of Interparfums Singapore Pte Ltd
- Chairman of the Board of Directors of Parfums Rochas Spain SL
- Sole Director of Interparfums Luxury Brands Inc. (United States)

Director of Inter España Parfums et Cosmétiques SL (Spain)

- Director of Interpartums Srl (Italy)

Vice Chair of the Supervisory Board and Chair of the Corporate Governance, Nominations and Remuneration Committee of Vivendi

Offices having expired in the last five years:

None.

Term of office to be renewed at the Annual General Meeting to be held in 2023.

Jean Madar

Director



Date of 1st appointment: December 23, 1993.

Date of last reappointment: April 27, 2018.

Jean Madar, 59, a graduate of the ESSEC business school, is the co-founder of the company with his partner Philippe Benacin. Jean Madar sets the strategic priorities for the New York-based Group Interparfums Inc. and development of the brands of the portfolio: Anna Sui, Dunhill, Oscar de la Renta, Abercrombie & Fitch, Hollister, Agent Provocateur, Guess, Bebe, MCM and Graff.

Current offices:

- Chief Executive Officer and director of Interparfums Holding
- Chief Executive Officer and Vice Chairman of the Board of Interparfums Inc. (United States)

Offices having expired in the last five years:

None.

Term of office to be renewed at the Annual General Meeting to be held in 2023.

Philippe Santi

Director and Executive Vice President



Date of 1st appointment: April 23, 2004. Date of last reappointment: April 27, 2018.

Philippe Santi, 59, graduate of the Neoma Business School (*Ecole Supérieur de Commerce of Reims*) with a degree as a public accountant, has served as the Chief Financial and Administrative Officer of Interparfums SA since 1995 and as Executive Vice President since 2004.

Current offices:

- Director of Interpartums Inc. (United States)

Offices having expired in the last five years:

None.

Term of office to be renewed at the Annual General Meeting to be held in 2023.

Frédéric Garcia Pelayo

Director and Executive Vice President



Date of 1st appointment: April 24, 2009. Date of last reappointment: April 27, 2018.

Frédéric Garcia Pelayo, 61, an EPSCI international exchange program graduate of the ESSEC Business School, has been Vice President for Export Sales of Interparfums since 1994 and Executive Vice President since 2004.

Current offices:

- Director of Interparfums Srl (Italy).
- Director of Inter España Parfums et Cosmétiques SL (Spain)
- Director and Vice President of Finance of TFWA

Offices having expired in the last five years:

None.

Term of office to be renewed at the Annual General Meeting to be held in 2023.

Patrick Choël

Director



Date of 1st appointment: December 1, 2004 Date of last reappointment: April 27, 2018.

Patrick Choël, 76, a graduate of Sciences Po Paris, was Chairman of the Fragrance and Cosmetics division of LVMH from 1995 to 2004.

Current offices:

- Director of Interparfums Inc. (United States).
- Director of Parfums Christian Dior


Offices having expired in the last five years:

- Director of Modelabs
- Director of SGD
- Director of ILEOS
- Director of Guerlain (November 2019)

Term of office to be renewed at the Annual General Meeting to be held in April 2021.

Véronique Gabai-Pinsky

Director



Date of 1st appointment: April 28, 2017.

Véronique Gabai-Pinsky, 55, a business school graduate of ESSEC, was Chair of the US company, Vera Wang, operating in the luxury ready-to-wear sector until June 2018.

Prior to joining Vera Wang, Ms. Gabai-Pinsky spent 12 years at the Estee Lauder Companies, as the Global President for Aramis and Designers Fragrances.

In the earlier years of her career, Ms. Gabai-Pinsky served as Vice President of Marketing and Communication for Guerlain, where she

successfully led projects including the re-launch of iconic Shalimar and the introduction of Aqua Allegoria.

She started her career at L'Oréal, and was lastly Vice President of Marketing for Giorgio Armani, where she was instrumental in the overall development of its fragrance business by developing the highly successful Acqua di Gio for men.

Current offices:

- Director of Interparfums Inc.


Member of The Committee of 200 (Fashion Group International and Cosmetic Executive Women)

Offices having expired in the last five years:

- Chair of the Vera Wang Group

Term of office expiring at the close of the Annual General Meeting in April 2021.

Maurice Alhadève



Independent director

Date of 1st appointment: April 23, 2004.

Date of last reappointment: April 27, 2018.

Maurice Alhadève, 77, a graduate of Sciences Po Paris and Northwestern University (Chicago) was the Chief Executive Officer of the Luxury division of "Française de soins et Parfums" (Unilever Group), and then, a manager for several companies specialized in the creation of fragrance concentrates: International Flavors and Fragrance (IFF), Créations Aromatiques and Haarmann & Reimer. He was head of the

ISIPCA, the school for the creation of fragrances, cosmetics and flavors, located in Versailles, France. He is today the cofounder and President of the Ecole Supérieure du Parfum de Paris, providing specialized programs in the fields of creation and management for the perfume industry.

Other appointments:

None.

Offices having expired in the last five years:

None.

Term of office to be renewed at the Annual General Meeting to be held in 2021.

Dominique Cyrot

Independent director



Date of 1st appointment: April 27, 2012.

Date of last reappointment: April 22, 2016.

Dominique Cyrot, 68, has a master's degree in management from Paris IX Dauphine University. Her professional career has included positions with the French insurer AGF from 1973 to 2011, which has become today ALLIANZ GI.

After heading the research department, then responsible for the insurance portfolio management for AGF, Dominique Cyrot was responsible for managing the UCTIS for the Group for French large caps

then for all French and European mid caps.

Up until 2000, Dominique Cyrot was a director of the investment funds Louxor (luxury), Agroplus (food industry), Galileo (high tech), and for Assystel and Geodis, two listed companies, as well as numerous SICAVs of the AGF Group and also external SICAVs .

Current offices:

- Director of FIME (SA) since April 16, 2015

Offices having expired in the last five years:

- Director of SECHE Environnement (office expired in April 2015)

Term of office expiring at the close of the Annual General Meeting in 2020.

Marie-Ange Verdickt

Independent director



Date of 1st appointment: April 24, 2015.

Date of last reappointment: April 27, 2018.

Marie-Ange Verdickt, 57, has a business degree from École Supérieure de Commerce de Bordeaux – KEDGE (1984), and is a member of the French Society of Financial Analysts (SFAF). She began her career as an auditor with Deloitte, then management controller for the computer group, Wang.

In 1990 she joined Euronext as a financial analyst and was subsequently appointed as head of the office of financial analysis. From 1998 until 2012,

she joined the asset management company, Financière de l'Echiquier, as a manager of equity funds specialized in French and European Mid-Caps. She also contributed to developing socially responsible investment practices. Since 2012, she has been an independent director in different companies.

Current offices:

- Member of the Supervisory Board of Wavestone (September 26, 2012)
- Member of the Supervisory Board of CapHorn Invest (May 31, 2013)
- Director of ABC Arbitrage (April 2013)
- Director of Bonduelle (December 2019)

Offices having expired in the last five years:

- Member of the Supervisory Board of Bonduelle (December 3, 2015 to December 5, 2019)

Term of office to be renewed at the Annual General Meeting to be held in 2023.

Chantal Roos

Independent director



cosmetic brands.

Date of 1st appointment: April 24, 2009.

Date of last reappointment: April 27, 2018.

Chantal Roos, 76, served as Vice-President for International Marketing then Deputy Chief Executive Officer within the Yves Saint Laurent Parfums Group, then Chair of Beauté Prestige Internationale.

She joined the Gucci group in 2000 as President of the Yves Saint Laurent Beauté division, becoming subsequently in 2007, Strategic Adviser to the Chairman and Chief Executive Officer. In 2008, she launched her own company specialized in the creation and development of fragrance and

Current offices:

- Managing Partner of CREA
- Managing Partner of ROOS&ROOS

Offices having expired in the last five years:

None.

Term of office to be renewed at the Annual General Meeting to be held in 2023.

Office of director submitted for renewal to the 2020 General Meeting

Dominique Cyrot

Independent director



Date of 1st appointment: April 27, 2012.

Date of last reappointment: April 22, 2016.

Dominique Cyrot, 68, has a master's degree in management from Paris IX Dauphine University. Her professional career has included positions with the French insurer AGF from 1973 to 2011, which has become today ALLIANZ GI.

After heading the research department, then responsible for the insurance portfolio management for AGF, Dominique Cyrot was responsible for managing the UCTIS for the Group for French large caps

then for all French and European mid caps.

Up until 2000, Dominique Cyrot was a director of the investment funds Louxor (luxury), Agroplus (food industry), Galileo (high tech), and for Assystel and Geodis, two listed companies, as well as numerous SICAVs of the AGF Group and also external SICAVs.

Current offices:

- Director of FIME (SA) since April 16, 2015

Offices having expired in the last five years:

- Director of SECHE Environnement (office expired in April 2015)

Audit Committee Members

Marie-Ange Verdickt

Audit Committee Chair

Independent director

Effective date of functions: 2015

Dominique Cyrot

Independent director

Effective date of functions: 2013

Patrick Choël

Director

Effective date of functions: 2010

Maurice Alhadève

Independent director

Effective date of functions: 2010

The operating procedures of the Audit Committee are described in article 6.2 of the Rules of Procedure and available for consultation on the Interpartums website.

https://www.interparfums.fr/bourse/information-reglementee.php

Report of the Board of Directors

Presentation of resolutions submitted to the Combined Ordinary and Extraordinary General Meeting of June 24, 2020

Approval of the annual and consolidated financial statements for the period ended December 31, 2019 Approval of non-deductible expenses (first and second resolutions)

We hereby request that you approve these annual financial statements for the period ended December 31, 2019 showing a profit of \leq 45,237,016 and the consolidated financial statements for the period ended December 31, 2019 as presented, showing a profit (attributable to equity holders of the parent) of \leq 50,633,000.

We also ask you to approve the total amount of disallowed deductions under article 39-4 of the French General Tax Code of €69,884 as well as the corresponding tax.

2. Approval of net income appropriation, setting the dividend (third resolution)

The appropriation of net income of our Company as proposed is in compliance with the law and our bylaws.

We accordingly ask you to appropriate the profit of the period of €45,237,016 as follows:

Inception

- Profit of the period	€ 45,237,016
Appropriation	
- Legal reserve	€ 1,288,969
- Retained earnings	€43,948,047

In accordance with the provisions of article 243 bis of the French general tax code, the dividends for the last three financial periods are disclosed below:

	Distributions eligible for the tax basis reduction		Bt-Lille . It
For the fiscal year	Dividends	Other distributions	Distributions not eligible for the tax basis reduction
2016	€ 19,529,831 ⁽¹⁾ or € 0.55 per share		
2017	€ 26,169,973 ⁽¹⁾ or € 0.67 per share		
2018	€ 30,505,596 ⁽¹⁾ or € 0.71 per share		

⁽¹⁾ Including the unpaid amount of dividends relating to treasury shares and allocated to retained earnings

3. Approval of regulated agreements (fourth resolution)

As a preliminary point, we remind you that only new agreements concluded during the last period ended and the beginning of the current in progress are submitted to this Meeting.

We hereby ask you to duly note the absence of any new agreement covered by article L. 225-38 of the French commercial code.

4. Directorships (fifth resolution)

We remind you that the term of office of Dominique Cyrot expires at the end of the next annual general meeting.

We propose that you renew her appointment for a term of five years expiring at the end of the annual general meeting that will be called in 2025 to approve the financial statements for fiscal year ended.

Independence and gender balance

We inform you that the Board of Directors, considers that Dominique Cyrot may be considered as an independent member with respect to the criteria of the Middlenext Code of corporate governance referred to by the Company for the purpose of corporate governance. With this respect, it is notably specified that she has no business relations with the Group.

Expertise, experience, skills and knowledge of the Group

The information concerning the expertise and experience of Dominique Cyrot, as a candidate are provided in Part 3, chapter 1.2.4, of the 2019 Universal Registration Document.

Should you approve this proposal to renew her term of office:

- The Board will continue to include four independent members and as such continue to comply with the recommendations of the Middlenext Code with respect to the percentage of independent directors.
- The percentage of women on the Board will be 40 % and in consequence in compliance with the law.
- The percentage of international members of the Board will be 10 %, with two nationalities represented.

5. Say on Pay (sixth to ninth resolutions)

In accordance with the provisions of L.225-37-2 of the French commercial code, it is proposed to the shareholders (sixth and seventh resolutions):

- By the 6th resolution, to approve the compensation policy for members of the Board of Directors;
- By the 7^{the} resolution to approve the compensation policy for the Chairman-Chief Executive Officer or any other executive officer.

The compensation policy of members of the Board of Directors, the Chairman-CEO and/or any other executive officer is presented in the report on corporate governance included in Part 3, chapter 3.2.1., of the 2019 Universal Registration Document and Appendix 1 of this Document.

Approval of the disclosures referred to in I of article L. 225-37-3 of the French commercial code (code de commerce)

In accordance with the provisions of article L.225-100 II of the French commercial code, shareholders at the General Meeting are asked, by the vote of the 8th resolution, to approve the disclosures mentioned in I of article L. 225-37-3 of the French commercial code, presented in the report on corporate governance included in Part 3, chapter 3.2.2 of the 2019 Registration Document and Appendix 2 of this Document

Approval of the fixed, variable or exceptional components of total compensation and benefits of any nature paid in the period ended or granted for the same period to Mr. Philippe Benacin, Chairman-Chief Executive Officer

By the vote of the 9th resolution, in accordance with the provisions of article L. 225-100 III of the French commercial code, the fixed, variable and exceptional components of compensation comprising the total compensation and benefits of any nature paid in the period ended or granted for the same period to Philippe Benacin, Chairman-CEO are subject to approval of the shareholders.

These components of compensation are presented in the report on corporate governance included in Part 3, chapter 3.2.3 of the 2019 Registration Document and Appendix 2 of this Document.

Proposal to renew the authorization concerning the implementation of the share repurchase program (tenth resolution) and the reduction of share capital by the cancellation of treasury shares (eleventh resolution)

We propose that under the terms of the tenth resolution, you grant the Board of Directors for a period of eighteen months, all powers necessary to purchase, on one or more occasions, at times of its choosing up to 5 % shares of the Company making up the share capital, where applicable adjusted to take into account increases or reductions in the share capital that may be carried out during the period the share buyback authorization is in force.

This authorization will cancel the authorization granted to the Board of Directors by the eleventh ordinary resolution of the general meeting of April 26, 2019.

Under this program, shares may be purchased for the following purposes:

- market making in the secondary market or ensuring the liquidity of the Interpartums share with an
 investment services provider through a liquidity agreement complying with market practice allowed by
 regulations, it being specified that the number of shares taken into account to calculate the abovementioned limit corresponds to the number of shares acquired, after deducting the number of shares
 resold.
- retaining shares purchased for subsequent use in exchange or as payment for acquisitions;
- ensuring sufficient shares are available for stock option and/or restricted share award (bonus share) plans (or equivalent plans) for the benefit of employees and/or corporate officers of the Group as well as all share grants in connection with a company or group employee savings plan (or equivalent plan), employee profit-sharing schemes and/or all other forms of share grants to employees and/or corporate officers of the Group;
- ensuring that sufficient shares are available to cover requirements for securities granting entitlement to shares of the Company in accordance with applicable regulations;
- canceling shares, as applicable, acquired in accordance with the authorization granted or to be granted by the Extraordinary General Meeting.

These shares may be purchased by any means, including through block purchases of shares, and at times deemed appropriate by the Board of Directors.

The Company does not intend to make use of options or derivatives.

We propose that the maximum purchase price be set at €50 per share and in consequence the maximum amount of the program at €118,155,475.

In light of tis the objective to cancel shares, under the terms of the eleventh resolution, we ask you to authorize Board of Directors, for a period of 24 months, to cancel, at its sole discretion, through one or more installments, subject to a limit of 10 % of the share capital calculated on the date of the cancellation decision, and deducting shares that may have been canceled during the 24 preceding months, shares the Company holds or may hold pursuant to share buybacks under this program to repurchase, and to reduce the share capital by the corresponding amount in compliance with applicable laws and regulations.

The Board of Directors will possess in consequence all powers necessary in such matters.

7. Financial authorizations

The Board of Directors wishes to benefit from financial authorizations to carry out, if it considers useful, any issues that may be found necessary within the framework of the development of the Company's activities, as well as from any authorizations necessary for the purpose of having an employee stock ownership incentive policy and promoting the company's development.

For this reason it is requested that you renew the financial authorizations which are expiring. In the list of delegations in progress, you will find in Part 3,, chapter 1.5 of the 2019 Registration Document and Appendix 4 of this Document, the list of the delegations of authority and authorizations granted to the Board of Directors by your General Meeting and a summary of their use.

In addition, in light of the financial authorizations that may eventually result in a capital increase for cash, you are requested to vote on the delegation of authority to increase the capital for the benefit of participants in an employee stock ownership plan, in accordance with applicable regulations.

7.1. Delegations of authority to issue ordinary shares and/or securities with or without shareholders' preferential subscription rights

The delegations of authority in this matter expire this year and have not been used.

We propose that you renew the delegations of authority to proceed with capital increases for cash consideration maintaining or canceling shareholders' preemptive subscription rights

The purpose of these delegations of authority is to grant the Board of Directors all necessary powers to carry out at times of its choosing, during a period of 26 months, the issuance of:

- ordinary shares;
- and/or ordinary shares granting entitlement to the allocation of other ordinary shares or debt securities;
- and/or securities giving access to ordinary shares to be issued.

7.1.1. Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities, and/or securities giving access to ordinary shares, maintaining shareholders' preferential subscription rights(twelfth resolution)

We propose that the total maximum nominal amount of ordinary shares able to be issued by virtue of this authority may not exceed €30,000,000. This amount may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital.

We propose that the total maximum nominal amount of debt securities of the Company able to be issued by virtue of this authority may not exceed €100,000,000.

The amount of issues that may be carried out on the basis of this resolution shall be independent of all other limits set by other resolutions of this Meeting.

With respect to this delegation, issues will be carried out by maintaining the shareholders' preferential subscription rights.

If applications for new shares on the basis of irrevocable entitlement subject to reduction (à titre réductible), and as the case may be, for excess shares on a non-preferential basis (à titre réductible), should fail to account for the entire issue, the Board of Directors may have recourse to the following options:

- limit the issue to the amount of applications received, as applicable, within the limits provided for by regulation,
- freely allocate all or part of the securities not taken up;
- offer all or part of the securities not taken up to the public.

This delegation of authority will supersede and cancel, for the unused portion, as applicable, any prior delegation of authority having the same purpose.

7.1.2. Delegations of authority providing for the cancellation of preferential subscription rights

7.1.2.1. Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities and/or securities giving access to ordinary shares, canceling shareholders' preferential subscription rights by a public offering (with the exception of offers covered by paragraph 1 of article L. 411-2 of the French financial and monetary code) and/or as consideration for security tendered in connection with a public exchange offer (thirteenth resolution).

Under this delegation of authority, issues will be carried out by a public offer, with the exception of offers covered by 1 of article L. 411-2 of the French financial and monetary code.

The preferential subscription rights of shareholders to ordinary shares and/or securities giving access to the share capital will be canceled whereby the Board of Directors will however have the option of giving shareholders priority subscription rights.

The total nominal amount of ordinary shares that may be issued by virtue of this authorization may not exceed ξ 9,000,000 representing approximately 6.3% of the share capital existing on the date of this meeting.

This amount may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital.

This amount shall be included under the overall limit concerning the maximum nominal amount of ordinary shares that may be issued set at 10 % of the share capital on the issue date.

The total nominal amount of debt securities of the company that may be issued by virtue of this authority may not exceed €50,000,000.

This limit will be independent of all other limits set by other resolutions of this general meeting.

The amount reverting or to revert to the company for each of the ordinary shares issued, after taking into account the issue price of share warrants, as applicable, will be determined in accordance with legal and regulatory provisions and shall at least equal the minimum required by the provisions of article R. 225-119 of the French commercial code on the date the Board of Directors implements this delegation of authority (the weighted average price of the last three trading sessions preceding the offer, minus, as applicable, a maximum discount of 10 %)

In the case of issuance of shares destined to be used in payment of securities tendered to the Company in connection with public exchange offers for securities, within the limits set forth above, the Board of Directors shall be vested with all necessary powers to draw up the list of securities to be tendered in the exchange, set the terms of the issue, the share exchange ratio, as well as, when applicable the balance to be paid in cash, and determine the procedures for the issue.

If applications for new shares should fail to account for the entire issue, the Board of Directors may have recourse to the following options:

- limit the amount of the issue to the amount of applications received, as applicable, within the limits provided for by regulation,
- freely allocate all or part of the securities not taken up;

This delegation of authority will supersede and cancel, for the unused portion, as applicable, any prior delegation of authority having the same purpose.

7.1.2.2. Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities, and/or securities giving access to ordinary shares, canceling the shareholders' preferential subscription rights (twelfth resolution)

Under this delegation of authority, issues will be carried out by means of an offer covered by 1 of article L. 411-2 of the French financial and monetary code.

The shareholders' preferential subscription right to ordinary shares and/or securities giving access to the share capital will be canceled.

The total nominal amount of ordinary shares that may be issued may not exceed $\[< \] 9,000,000 \]$ representing approximately 6.3% of the share capital existing on the date of this meeting, and shall be furthermore capped at 20% of the share capital per year.

This amount may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital.

This amount shall be included under the overall limit concerning the maximum nominal amount of ordinary shares that may be issued set at 10 % of the share capital on the issue date.

The total nominal amount of debt securities of the company that may be issued by virtue of this authority may not exceed €15,000,000.

This limit will be independent of all other limits set by other resolutions of this general meeting.

The amount reverting or to revert to the company for each of the ordinary shares issued, after taking into account the issue price of share warrants, as applicable, will be determined in accordance with legal and regulatory provisions and shall at least equal the minimum required by the provisions of article R. 225-119 of the French commercial code on the date the Board of Directors implements this delegation of authority (the weighted average price of the last three trading sessions preceding the offer, minus, as applicable, a maximum discount of 10 %)

If applications for new shares should fail to account for the entire issue, the Board of Directors may have recourse to the following options:

- limit the amount of the issue to the amount of applications received, as applicable, within the limits provided for by regulation,
- freely allocate all or part of the securities not taken up;

This delegation of authority will supersede and cancel, for the unused portion, as applicable, any prior delegation of authority having the same purpose.

7.1.2.3. Authorization, in the case of an issue entailing the cancellation of the preferential subscription right, to set, within the limit of 10 % of the share capital per year, the issue price according to the conditions set by the Meeting (fifteenth resolution)

We propose, in accordance with the provisions of article L. 225-136 1, subsection 2 of the French commercial code, that you authorize the Board of Directors who decides to proceed with an issue of ordinary shares or securities giving access to the share capital entailing the cancellation of preferential subscription rights by an offer to the public and by private placement (thirteenth and fourteenth resolutions) subject to the provisions of article L. 225-136 1°, subsection 1 of the French commercial code to derogate within the limit of 10 % of the share capital per year from the conditions for setting the price provided for in the aforementioned resolutions and set the issue price for equity equivalent securities to be issued as follows:

The share price for equity equivalent securities to be issued immediately or in the future, may not be less, at the Board of Directors' choice, to one of the following amounts:

either the weighted average price of the Company's share on the day preceding the beginning of the offer, minus, as applicable, a discount of up to 20 %,

- or the average trading price for five consecutive days selected from within a period of the thirty trading days preceding the beginning of the offer, minus a possible discount of up to 20 %

This derogating rule with respect to price may provide the board with a certain degree of flexibility in setting the amount of the discount when setting the issue price according to the nature of the corporate action and the situation of the market, and the average reference price.

This authorization will supersedes and cancel any prior authorization having the same purpose.

7.1.3. Authorization to increase the amount of issues in the case of oversubscription(sixteenth resolution)

We propose, within the framework of the aforementioned delegations of authority for maintaining and canceling the preferential subscription rights (twelfth to fourteenth resolutions), to grant the Board of Directors the ability to increase, under the conditions provided for by articles L 225-135-1 and R 225-118 of the French commercial code, and within the limits set by the general meeting, the number of shares provided for under the initial issue.

Accordingly, the number of securities may be increased within 30 days after the close of the subscription period within the limit of 15 % of the initial issue and the same price as the initial issue, within the maximum limits set by the general meeting.

This authorization will supersedes and cancel any prior authorization having the same purpose.

7.1.4. Delegation of authority to increase the share capital as consideration for in-kind contributions of securities (seventeenth resolution)

To facilitate the payment of acquisitions, we ask that you grant the Board of Directors a delegation of authority to increase the share capital by the issuance of ordinary shares or securities giving access to ordinary shares as consideration for contributions in kind granted to the Company and consisting of equity securities or securities giving access to the capital.

This delegation would be granted for a period of 26 months.

The total nominal amount of ordinary shares that may be issued by virtue of this delegation of authority may not exceed 10 % of the share capital, without taking into account the nominal amount of the capital increase required, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, to preserve the rights of holders of securities giving access to the Company's capital.

This amount shall be included under the overall limit concerning the maximum nominal amount of ordinary shares that may be issued set at 10 % of the share capital on the issue date.

This delegation of authority will supersede and cancel, for the unused portion, as applicable, any prior delegation of authority having the same purpose.

Delegation of authority to increase the capital for the benefit of participants in a company savings plan (eighteenth resolution)

We submit this resolution to your vote in order to comply with article L.225-129-6 of the French commercial code, whose terms require the Extraordinary General Meeting to also vote on a resolution opposing a

capital increase under the conditions provided for in article L.3332-18 et seq. of the French labor code when it delegates its authority to proceed with capital increase by consideration in cash.

As the General Meeting has been called to vote on delegations of authority which may result in capital increases in cash, it is also required to vote on a delegation for the benefit of participants in a company savings plan.

Under the terms of this delegation of authority, it is asked that you authorize the Board of Directors to increase the share capital, at once or in installments, by issuing ordinary shares or securities giving access to the company's capital in favor of participants in one or more company or group employee stock ownership plans established by the company and/or French or foreign companies affiliated with it, in accordance with the provisions of article L. 225-180 of the French commercial code and article L. 3344-1 of the French labor code.

In application of the provisions of Article L.3332-21 of the French labor code, the Board of Directors may provide for grants without consideration to beneficiaries, of shares to be issued or already issued or other securities giving access to the Company's share capital to be issued or already issued, with respect to (i) contributions that may be paid in accordance with procedures for company or group stock ownership plans and/or (ii), as applicable, the share price discount.

As required by law, the General Meeting would cancel the shareholders' preferential subscription rights.

The maximum nominal amount of the capital increases that may be carried out under this delegation of authority shall be 2% of the share capital on the date the Board of Directors' decides to proceed with this capital increase

This amount shall be included under the overall limit concerning the maximum nominal amount of ordinary shares that may be issued set at 10 % of the share capital on the issue date.

This amount may be increased, as necessary, by the nominal amount of the capital increase necessary, in accordance with the law, and, as the case may be, applicable contractual provisions providing for other methods for preserving rights, to preserve rights of holders of rights or securities giving access to the company's capital.

This delegation would be for a period of 26 months.

It is specified that in accordance with the provisions of article L. 3332-19 of the French labor code, the price of the shares to be issued may not be more than 30 % or 40 % below, when the lock-up period provided for under the plan in accordance with Articles L. 3332-25 and L. 3332-26 of the French labor code is greater than or equal to ten years, the average opening price for the twenty trading sessions preceding the date of the decision setting the opening date of the subscription nor greater than this average.

The Board of Directors will be vested with, within the limits set forth above, all powers necessary notably to set the terms and conditions of the issue or issues, record the completion of the resulting capital increases, amend the bylaws in consequence, charge at its sole discretion the costs of the capital increase to the corresponding share premium and appropriate therefrom all amounts required to ensure that the legal reserve represents one tenth of the new share capital after each increase, and in general, take all actions required.

This delegation of authority will supersede and cancel, for the unused portion, as applicable, any prior delegation of authority having the same purpose.

9. Aggregate limit of the ceilings of delegations of authority provided for by the thirteenth, fourteenth, seventeenth and eighteenth resolutions of this general meeting (nineteenth resolution)

We propose to set at 10 % of the amount of share capital on the issue date, the total number of ordinary shares that may be issued, immediately or in the future, provided for in the thirteenth, fourteenth, seventeenth and eighteenth resolutions of this Meeting, it being specified that this amount may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital.

10. Modifications of the bylaws (twentieth to twenty-second resolutions)

We propose that you modify article 14 of the bylaws, in accordance with article L. 225-37 of the French commercial code as amended by French law No. 2019-744 of July 19, 2019 on the simplification of company in order to provide for:

- on the one hand, in the 20th resolution, the possibility for members of the Board of Directors to make decisions relating to their own functions by means of a written consultation, which are listed exhaustively by regulation.

This option may be implemented for the following decisions:

- the co-optation of members;
- authorizing security interest, endorsements and guarantees;
- pursuant to a delegation of authority by the Extraordinary General Meeting, legal and regulatory provisions;
- calling the general meeting of shareholders;
- transferring the registered office to another location in the same department in France
- and on the other hand, in the 21st resolution, provide for the option of participating in certain meetings
 of the Board of Directors by means of videoconferencing or telecommunications technologies and
 modifying the list of decisions that may be adopted by said Meeting in order include only those subject
 to legal exclusions.

This option may be implemented for the following decisions:

- appointment of the Chairman and/or Chief Executive Officer;
- removal of the Chief Executive Officer.

We propose also, in the 22^{nd} resolution, to modify article 16 of the bylaws concerning the procedures for exercising the executive management in order to limit the constraint linked to the length adopted by the Board with respect to these procedures.

11. Harmonization of the bylaws (twenty third resolution)

We propose that you harmonize the bylaws with the applicable laws and regulations:

1) Concerning the identification of holders of bearer shares:

We propose that you harmonize article 12 of the bylaws with the provisions of articles L. 228-2 of the French commercial code as amended by Law No. 2019-486 of May 22, 2019 concerning the identification of holders of bearer shares modifying the procedures for identifying bearer shareholders.

2) Concerning ordinary agreements:

We propose that you harmonize article 18 of the bylaws concerning ordinary agreements entered into under normal conditions by replacing the reference to article L. 225-38 of the French commercial code by a reference to article L. 225-39 of said code.

3) Concerning the textual reference to the signature of electronic forms:

We propose that you harmonize article 19 of the bylaws with the provisions of Ordinance No. 2016-131 of February 10, 2016 on the reform of contract law, the general regime and proof of obligations resulting in a re-codification of the provisions of the French Civil Code relating to the electronic signature, and replacing in consequence the reference to article 1316-4 Civil Code by a reference to article 1367 of the same code.

4) Concerning the invalidation or modification of the proxy or vote expressed before the record date:

We propose that you harmonize article 19 with the provisions of article L. 225-85 of the French commercial code as amended by Decree No. 2014-1466 of December 8, 2014, amending the date and procedures for establishing the list of persons authorized to participate in meetings of shareholders and bondholders of commercial companies by replacing the reference in the case of the disposal of shares intervening before the record date by a reference to the transfer of title.

12. Textual references applicable in the case of a change in codification (twenty fourth resolution)

We ask you to duly note that the textual references mentioned in all resolutions of this Meeting make reference to the legal and regulatory provisions applicable on their date of establishment and that in the event of a modification of the notification thereof in connection with the authorization granted by Law No. 2019-486 of May 22, 2019 to the government, the textual references corresponding to this new qualification will replace the former.

The Board of Directors invites you to vote in favor the resolutions which have been submitted to you.

Appendix 1

Compensation policy for corporate officers (6th and 7th resolutions of the AGM of June 24, 2020)

In light of the recommendations of the Middlenext Code of corporate governance, the Board of Directors has established a compensation policy for each corporate officer of the company in the interest of the company by contributing to its long-term development and in line with its commercial strategy as described in section 1 "Consolidated management report", paragraph 1 "The Company's business and strategy" of the 2019 Universal Registration Document.

No component of compensation of any nature may be set, allocated or paid by the Company and no undertaking may be made by the Company if not in compliance with the approved compensation policy or, in the absence thereof, with compensation or practices existing within the Company.

The Board sets, revises and implements the compensation policy for each corporate officer. When the Board of Directors rules on a component of compensation or a commitment for the benefit of its Chairman, and Chief Executive Officer(Directeur Général) or an Executive Vice President (Directeur Général) Délégué), the party thus concerned abstains from participating in the proceedings or voting on the components of compensation or commitment in question.

1/ Compensation policy for the Chairman-Chief Executive Officer or any other executive officer

The policy described below applies to the Chief Executive Officer as well as any other executive officer to whom compensation may be allocated on the basis of their office.

In this respect, it is specified, for information purposes, that the current executive vice presidents do not receive any compensation with respect to their offices. These officers are bound to the Company by permanent employment contracts whose characteristics are described in Part 3 "Corporate governance", chapter 2.1.3. of the 2019 Universal Registration Document.

In addition, the terms of office of executive officers are described in Part 3, chapter 1.2.4. of the 2019 Registration Document.

Variable and fixed compensation

The compensation policy set by the Board is as follows:

The fixed, variable and special components of total compensation and benefits of any nature attributable to the Chairman-CEO on the basis of his office, as well as their respective importance are as follows:

- fixed compensation: this is determined each year in relation to changes in responsibilities or events affecting the company, the environment for the business and the market of reference, and must be proportionate to the situation of the company and will be paid through monthly payments.
- annual variable compensation: this is based on clearly defined, quantifiable and operational objectives and contingent on the achievement of financial objectives on the one hand, and qualitative objectives on the other. It may account for up to 60 % of total compensation.

The Board of Directors on January 20, 2020 defined qualitative criteria and a new breakdown between quantitative and qualitative objectives, with the first accounting for 60 % and the second 40 % of the total.

For each of these quantitative and qualitative objectives, a minimum threshold of meeting 80 % of the objectives set is required to justify payment of the variable compensation.

Went the rate of achievement reaches $125\,\%$ of the objectives set, the amount of variable remuneration due will be then increased by $25\,\%$.

The criteria for setting annual compensation are as follows:

- financial and quantitative criteria: these financial criteria are based on a target for consolidated sales and consolidated operating profit, with each of the criteria given equal weight in determining variable compensation.
- non-financial criteria: the qualitative criteria have been established in a precisely defined manner linked to the growth strategy of the Company and its subsidiaries.

The level of achievement expected for the quantitative financial criteria as well as the non-financial criteria were previously established by the Board of Directors though not rendered public for reasons of confidentiality and in light of the sensitivity of this information with respect to strategy and the competition.

Other compensation

• Multi-year variable compensation and special compensation

There is no plan for the payment of multi-year compensation or exceptional compensation.

• Performance share awards – stock options

The shareholders' AGM of April 26, 2019 authorized the Board of Directors to award restricted stock units and/or stock options and/or stock purchase options of the company to members of personnel and/or selected corporate officers. In this framework, the Chair-CEO may be awarded in 2020 restricted stock units and/or stock options and/or stock purchase options subject to conditions of performance and holding periods linked to his term as officer of the company.

• Compensation awarded to directors on the basis of their office

The Chairman-CEO and Executive Vice Presidents, in their capacity as directors, have expressly waived their right to receive compensation to which they might be entitled as members of the Board.

· Benefits of any nature

The Chairman-CEO benefits from the use of a company car representing a benefit in kind.

No other benefits in kind are granted to him.

2/ Compensation policy for Board members

The 13th resolution of the ordinary Annual General Meeting of April 27, 2018 set as compensation for members of the Board of an annual amount of €200,000 valid for the 2018 financial year until a new decision by the Annual General Meeting.

The criteria for distributing this fixed annual amount allocated by the Annual General Meeting to members of the Board were set by the Board and are as follows:

- meeting attendance;
- audit Committee membership.

The compensation policy for Board members is based on an allocation reserved exclusively to outside non-executive directors serving on the Board of Directors. The other directors expressly waived their entitlement to receive compensation.

No other form of compensation is paid to non-executive directors.

3/ Information on offices and employment contracts and/or service agreements of corporate officers with the Company

The following table indicates the terms of offices of officers of the Company and, as applicable, employment contracts or service agreements entered into with the Company the notice periods and the conditions for revocation or termination applicable thereto;

Officers of the Company	Philippe Benacin	Frédéric Garcia Pelayo	Philippe Santi
Office(s) exercised	Chairman-Chief Executive Officer	Executive Vice President	Executive Vice President
Length of the offices	At the end of the AGM to be held in 2023 called to approve the financial statements		
Employment contract entered into with the company (specify its term)	No	Yes – permanent employment contract for the position of "Chief International Officer"	Yes - permanent employment contract for the position of "Chief Financial and Legal Officer"
Service agreements entered into with the Company	No	No	No
Notice periods	N/A	3 month notice period for salaried positions	
Conditions for revocation or termination	Revocation of the office as provided by law and jurisprudence	·	
		Termination of the office as provided by law and jurisprudence	

Appendix 2

Disclosures required by article L. 225-37-3 of the French commercial code for each officer of the Company (8th resolution of the AGM of June 24, 2020)

It is specified that the total compensation of the Chairman-CEO is in compliance with the compensation policy relating thereto as approved by the 10th resolution of the Annual General Meeting of April 26, 2019. Readers are reminded that the Company's two Executive Vice Presidents (*Directeurs Généraux Délégués*) receive compensation exclusively on the basis of their employment contract.

1/ Summary of compensation, stock options and shares awarded to each executive officer

	Fiscal 2018	Fiscal 2019
Mr. Philippe Benacin - Chairman and Chief Executive Officer		
Compensation allocated for the year	€ 599,800	€ 589,800
Valuation of options granted in the period (Interparfums Inc. Plan)	\$ 366,500	\$ 353,000
Measurement of multi-year compensation plans	N/A	N/A
Valuation of performance shares granted in the period	€ 119,360	-

	Fiscal 2018	Fiscal 2019
Philippe Santi - Director - Executive Vice President		
Compensation allocated for the year	€ 714,000	€710,000
Valuation of options granted in the period (Interpartums Inc. Plan)	\$ 189,760	\$ 141,200
Measurement of multi-year compensation plans	N/A	N/A
Valuation of performance shares granted in the period	€ 119,360	-
Frédéric Garcia-Pelayo - Director - Executive Vice President		
Compensation allocated for the year	€ 721,800	€717,800
Valuation of options granted in the period (Interparfums Inc. Plan)	\$ 189,760	\$ 141,200
Measurement of multi-year compensation plans	N/A	N/A
Valuation of performance shares granted in the period	€ 119,360	-

No other compensation or benefits of any nature was received by the Chairman-CEO and the Executive Vice Presidents in 2019 from controlled companies and the controlling company.

2/ Summary of compensation for each executive officer

	Fiscal 2018			Fiscal 2019
	Compensation allocated for the year	Compensation paid in the year	Compensation allocated for the year	Compensation paid in the year
Mr. Philippe Benacin - Cha	irman and Chief Exe	cutive Officer		
Fixed compensation	444,000	444,000	456,000	456,000
Variable compensation	145,000	147,000	123,000	146,000
Exceptional compensation	-	-	-	-
Compensation allocated on the basis of his office as Board member	-	-	-	-
Benefits in kind (vehicle)	10,800	10,800	10,800	10,800
Total	599,800	601,800	589,800	612,800

		Fiscal 2018		Fiscal 2019
	Compensation allocated for the year	Compensation paid in the year	Compensation allocated for the year	Compensation paid in the year
Philippe Santi - Director - E	xecutive Vice Presid	ent		
Fixed compensation	384,000	384,000	396,000	396,000
Variable compensation	330,000	318,000	314,000	331,500
Exceptional compensation	-	-	-	-
Compensation allocated on the basis of his office as Board member	-	-	-	-
Benefits in-kind	-	-	-	-
Total	714,000	702,000	710,000	727,500
Frédéric Garcia-Pelayo - D	Director - Executive V	ice President		
Fixed compensation	384,000	384,000	396,000	396,000
Variable compensation	330,000	318,000	314,000	331,500
Exceptional compensation	-	-	-	-
Compensation allocated on the basis of his office as Board member	-	-	-	-
Benefits in kind (vehicle)	7,800	7,800	7,800	7,800
Total	721,800	709,800	717,800	735,300

3/ Compensation received by non-executive directors

Non-executive officers	Compensation allocated and paid in 2018	Compensation allocated and paid in 2019
Maurice Alhadève	€ 34,000	€ 32,000
Patrick Choël	€ 30,000	€ 28,000
Ms. Dominique Cyrot	€ 30,000	€ 22,000
Ms. Chantal Roos	€ 28,000	€ 20,000
Ms. Marie-Ange Verdickt	€ 30,000	€ 28,000
Ms. Véronique Gabai-Pinsky	€ 28,000	€ 16,000

This concerns solely compensation paid on the basis of their offices as director

Employment

contract

The compensation of Mr. Madar is presented in chapter 2.4., Part 3 of the 2019 Universal Registration Document.

4/ Summary of employment contracts, specific retirement benefits, severance benefits and non-compete clauses of executive officers

retirement plan

Supplemental Compensation or

benefits due on

termination or

following a

change of

Compensation

resulting from a

non-compete

clause

			position	
Mr. Philippe Benacin - Chairman a	and Chief Executive (Officer		
Date of last reappointment: 04/27/18	No	Yes	No	No
End of term: AGM 2023				
Philippe Santi - Director - Executiv	e Vice President			
Date of last reappointment: 04/27/18	Yes	Yes	No	No
End of term: AGM 2023				
Frédéric Garcia-Pelayo - Director	- Executive Vice Pres	sident		
Date of last reappointment: 04/27/18	Yes	Yes	No	No

Senior executives benefit from a supplemental retirement plan in the form of a defined contribution annuity fund.

End of term: AGM 2023

The benefits of this defined benefit plan were subsequently extended to management employees of the Company. This contribution to a private defined contribution pension fund is paid in part by the beneficiaries and in part by the employer for an amount equal four times French Social Security ceiling. The annual contribution to this fund per executive officer beneficiary is €15,000. The supplemental retirement plan is part of the overall compensation policy adopted by the Company for senior executives and managers.

No executives benefit from forms of remuneration, indemnities or benefits owed or which could be owed resulting from the assumption, termination or change of functions of corporate officer of the Company or subsequent to these events.

5/ Pay ratios

These ratios are calculated in accordance with article L. 225-37-3 paragraph 6 as recently modified by the PACTE Act for the Business Growth and Transformation Action Plan No. 2019-486 of May 22, 2019 (plan d'action pour la croissance et la transformation des entreprises or "PACTE") in the interest of ensuring conformity with new requirements for transparency about executive compensation.

The following summary presents, on the one hand, the ratio between the level of compensation of the Chief Executive Officer-CEO and the Executive Vice Presidents of the Company (fixed and variable compensation) and the average compensation of employees (excluding officers) and on the other hand, the ratio in relation to the median for employee compensation (excluding officers) of the Company as well as the changes in these two ratios over the last five years.

		2015	2016	2017	2018	2019
Philippe Benacir	Chairman and Chief Exec	cutive Officer				
Pay ratios	Average	6.93	6.82	6.44	7.15	6.95
	Median	9.17	8.77	8.39	9.57	9.57
Philippe Santi	Executive Vice President	and CFO,				
Pay ratios	Average	7.97	8.05	8.75	8.50	8.40
	Median	10.55	10.35	11.41	11.36	11.57
Frédéric Garcia-	Pelayo Executive Vice	President				
Pay ratios	Average	7.97	8.05	8.75	8.50	8.40
	Median	10.55	10.35	11.41	11.36	11.57

Appendix 3

Fixed, variable and exceptional components of total compensation and benefits of any nature paid in the period ended or awarded for the period ended to the Chairman-CEO (9th resolution of the AGM of June 24, 2020)

At the Annual General Meeting of June 24, 2020, shareholders will be asked to approve the fixed, variable or exceptional components of total compensation and benefits of any nature paid or granted for the period ended to Mr. Philippe Benacin, Chairman-CEO.

After determining that 100 % of the objectives set for Philippe Benacin for 2019, had been met, on January 20, 2020, the Board of Directors set the variable portion of annual compensation at a gross amount of € 123,000.

Components of compensation paid or granted for fiscal 2019	Amounts or accounting valuations submitted to vote	Description
Fixed compensation	€ 456,000 Amount paid	
Annual variable compensation paid in fiscal 2019	€ 146,000	
Annual variable compensation allocated for fiscal 2019	€ 123,000 Amount to be paid after approval by the 2020 AGM	60 % of the quantitative objectives (2019 consolidated revenue and operating profit) and 40 % of the qualitative objectives (4 components relating to the growth strategy and management of the Rochas fashion business)
Bonus share issues	-	-
Benefits of any nature	€ 10,800 Accounting valuation	Use of a company car

Appendix 4

Summary of delegations of authority and financial authorizations granted by the General Meeting to the Board of Directors (Art. L. 225 129-1 and L. 225-37-4 of the French commercial code)

Summary of delegations of authority and financial authorizations in force

Nature of the delegations of authority and authorizations	Limits of the issue	Delegations of authority and authorizations used	Expiration date
Delegations of authority and a	uthorizations granted by th	e 2019 AGM	
Delegation of authority to increase the capital by capitalizing reserves, earnings or premiums (12th resolution)	Within the limit of €50,000,000	Delegation of authority used by the Board of Directors' meetings of April 26, 2019, creating 4,296,562 new shares in the amount of €12,889,686	06/25/21
Authorization to grant stock options to employees or selected corporate officers (13th resolution)	Within the limit of 1 % of the share capital on the grant date	Unused	06/25/22
Authorization to award restricted share awards (actions gratuites or bonus shares) to employees and/or selected corporate officers(15th resolution)	Within the limit of 3 % of the share capital on the grant date	Unused	06/25/22
Delegation of authority to issue shares reserved for employees of the Group participating in a company savings plan (15th resolution)	Within the limit of 2 % of the share capital on the issue date ⁽¹⁾	Unused	06/25/21

Nature of the delegations of authority and authorizations	Limits of the issue	Delegations of authority and authorizations used	Expiration date
Delegations of authority and a	uthorizations granted by the	e 2018 AGM	
Delegation of authority to issue shares or securities, maintaining shareholders' preferential subscription rights (20th resolution)	Within the limit of €30,000,000 (shares) and €100,000,000 (debt securities)	Unused	06/26/20
Delegation of authority to issue shares or securities, canceling shareholders' preferential subscription rights through a public offering (21st resolution)	Within the limit of €9,000,000(1) (shares) and €50,000,000 (debt securities)	Unused	06/26/20
Delegation of authority to issue shares or securities giving access to the capital of the company, canceling shareholders' preferential subscription rights through an offering covered by article L.411-2of the French monetary and financial code (22nd resolution)	Within the limit of €9,000,000 ⁽¹⁾ (shares) and €15,000,000 (debt securities)	Unused	06/26/20
Increase in the number of shares to be issued in the case of excess demand and a capital increase with or without shareholders' preferential subscription rights (24th resolution)	Within the limit of 15 % of the initial issue	Unused	06/26/20
Authorization to issue shares or securities giving access to the capital as consideration in payment for in-kind contributions of equity securities (25th resolution)	Within the limit of 10 % of the share capital on the date of the AGM ⁽¹⁾	Unused	06/26/20
Delegation of authority to issue shares reserved for employees of the Group participating in a company savings plan (26th resolution)	Within the limit of 2 % of the share capital on the issue date(1)	Unused	06/26/20

⁽¹⁾ Included within the total ceiling of 10 % of the share capital on the issue date (27th resolution of the 2018 AGM).



Draft resolutions

Ordinary resolutions

First resolution

Approval of the annual financial statements for the period ended December 31, 2019 - Approval of non-deductible expenses

The shareholders, after having considered the reports of the Board of Directors and the Auditors for the period ended December 31, 2019, approve the financial statements as presented showing on this date net income of €45,237,016.

The shareholders furthermore approve the total amount of disallowed deductions under article 39-4 of the French General Tax Code of €69,884 as well as the corresponding tax.

Second resolution

Approval of the consolidated financial statements for the period ended December 31, 2019

The shareholders, after having considered the reports of the Board of Directors and the auditors on the consolidated financial statements for the period ended December 31, 2019, approve these financial statements as presented showing on this date a net profit (attributable to equity holders of the parent) of €50,633,000.

Third resolution

Appropriation of net income of the period

The shareholders, on the Board of Directors' proposal, decide to appropriate net income for the fiscal period ended December 31, 2019 as follows:

Inception

- Profit of the period	€ 45,237,016
Appropriation	
- Legal reserve	€ 1,288,969
- Retained earnings	€43,948,047

In accordance with the provisions of article 243 bis of the French general tax code, shareholders shall duly note that dividends for the last three financial periods were as follows:

	Distributions eligible for the	tax basis reduction	Diabibutions
For the fiscal year	Dividends	Other distributions	Distributions not eligible for the tax basis reduction
2016	€ 19,529,831 ⁽¹⁾ or € 0.55 per share		
2017	€ 26,169,973 ⁽¹⁾ or € 0.67 per share		
2018	€ 30,505,596 ⁽¹⁾ or € 0.71 per share		

⁽¹⁾ Including the unpaid amount of dividends relating to treasury shares and allocated to retained earnings

Fourth resolution

Statutory Auditors' special report on regulated agreements and commitments - Recognition of the absence of new agreements

The shareholders, after reviewing the auditors' special report indicating the absence of any new agreements of the type mentioned in articles L.225-38 et seq. of the French commercial code, duly note their conclusions.

Fifth resolution

Reappointment of Mrs. Dominique Cyrot as director

The shareholders decide to renew Dominique Cyrot's appointment as director for a term of five years expiring at the end of the annual general meeting that will be called in 2025 to approve the financial statements for fiscal year ended.

Sixth resolution

Approval of the compensation policy for members of the Board of Directors

The shareholders, ruling in accordance with article L. 225-37-2 of the French commercial code, approve the compensation policy for members of the Board of Directors presented in the report on corporate governance included in paragraph 2.1.2 of the 2019 Universal Registration Document.

Seventh resolution

Approval of the compensation policy for the Chairman-Chief Executive Officer and/or any other executive officer

The shareholders, ruling in accordance with article L. 225-37-2 of the French commercial code, approve the compensation policy for the Chairman-CEO and/or any other executive officer presented in the report on corporate governance included in paragraph 2.1.1 of the 2019 Universal Registration Document.

Eighth resolution

Approval of the disclosures referred to in I of article L. 225-37-3 of the French commercial code (code de commerce)

The shareholders, ruling in accordance with article L. 225-100 II of the French commercial code, approve the information covered by article L. 225-37-3 of the French commercial code mentioned in the in the report on corporate governance included in paragraph 2.2 of the 2019 Universal Registration Document.

Ninth resolution

Approval of the fixed, variable or exceptional components of total compensation and benefits of any nature paid in the period ended or granted for the same period to Mr. Philippe Benacin, Chairman-Chief Executive Officer

The shareholders, ruling in accordance with article L.225-100 subsection III of the French commercial code, approve the fixed, variable or exceptional components making up the total compensation and benefits of any nature paid in the period in progress or granted for the period ended to Mr. Philippe Benacin, Chairman-Chief Executive Officer, as presented in the Report on Corporate Governance, section 2.3, of the Universal Registration Document.

Tenth resolution

Authorization to be granted to the Board of Directors for dealing in own shares within the framework of article L.225-209 of the French commercial code

The shareholders, after considering the Board of Directors' report, grant the latter an authorization for eighteen months in accordance with the provisions of articles L. 225-209 et seq. of the French commercial code, to purchase, on one or more occasions at times of its choosing up to 5 % the number of shares of the Company making up the share capital, where applicable adjusted to take into account increases or reductions in the share capital that may be carried out during the period the share buyback authorization is in force.

This authorization cancels the authorization granted to the Board of Directors by the eleventh ordinary resolution of the general meeting of April 26, 2019.

Under this program, shares may be purchased for the following purposes:

- market making in the secondary market or ensuring the liquidity of the Interpartums share with an
 investment services provider through a liquidity agreement complying with market practice allowed by
 regulations, it being specified that the number of shares taken into account to calculate the abovementioned limit corresponds to the number of shares acquired, after deducting the number of shares
 resold.
- retaining shares purchased for subsequent use in exchange or as payment for acquisitions;
- ensuring sufficient shares are available for stock option and/or restricted share award (bonus share) plans (or equivalent plans) for the benefit of employees and/or corporate officers of the Group as well as all share grants in connection with a company or group employee savings plan (or equivalent plan), employee profit-sharing schemes and/or all other forms of share grants to employees and/or corporate officers of the Group;
- ensuring that sufficient shares are available to cover requirements for securities granting entitlement to shares of the Company in accordance with applicable regulations;
- canceling shares, as applicable, acquired in accordance with the authorization granted or to be granted by the Extraordinary General Meeting.

These shares may be purchased by any means, including through block purchases of shares, and at times deemed appropriate by the Board of Directors.

The Company does not intend to make use of options or derivatives.

The maximum purchase price is € 50 per share; In the case of equity transactions including notably stock splits or reverse stock splits or bonus share grants to shareholders, the amount indicated above will be adjusted in the same proportions (with the multiplier being equal to the ratio between the number of shares making up the share capital before the transaction and the number of shares thereafter).

The maximum amount for the purchase of shares under this authorization is €118, 155,475.

The shareholders grant all powers to the Board of Directors to proceed with these transactions, set the terms and conditions and procedures, conclude all agreements and fulfill all formalities.

Extraordinary resolutions

Eleventh resolution

Authorization to be granted to the Board of Directors to cancel shares purchased by the Company in connection with article L.225-209 of the French Commercial Code

The shareholders, after considering the Board of Directors' report and the Auditors' report:

- 1) Authorize the Board of Directors to cancel, at its sole discretion, through one or more installments, subject to a limit of 10 % of the share capital calculated on the date of the cancellation decision, and deducting shares that may have been canceled during the 24 preceding months, shares the Company holds or may hold pursuant to share buybacks undertaken in accordance with article L. 225-209 of the French commercial code, and reduce the share capital by the corresponding amount in compliance with applicable laws and regulations,
- 2) Set the period of validity of this delegation of authority at twenty-four months from the date of this meeting,
- 3) Grant the Board of Directors all powers to take measures required to complete such cancellations and the corresponding reductions in share capital, to amend the company's bylaws as a result and to carry out all formalities required.

Twelfth resolution

Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities (of the Company or a Group company), and/or securities giving access to ordinary shares (by the Company or a Group company), maintaining shareholders' preferential subscription rights

The shareholders, having considered the Board of Directors' report and the Auditors' special report, in accordance with the provisions of the French commercial code and particular, articles L. 225-129-2, L. 228-92 and L. 225-132 et seq.:

- 1) Grant the Board of Directors authority to proceed with the issue, for valuable consideration or free of consideration, through one or more installments, in amounts and at such times it chooses, in France and/or international markets, either in euros or in another currency, or in any other monetary unit established by reference to several currencies,
- ordinary shares;
- and/or ordinary shares granting entitlement to the allocation of other ordinary shares or debt securities;
- and/or securities giving access to ordinary shares to be issued.

In accordance with article L. 228-93 of the French commercial code, securities to be issued may give access to ordinary shares to be issued by any company which directly or indirectly holds more than half of its capital or a company in which it directly or indirectly holds more than half of its capital.

- 2) Set the duration for this authorization provided for under this resolution at twenty-six months from the date of this Meeting.
- 3) Decide to set, as follows, the limits of the amounts for issues authorized if the Board of Directors makes use of this delegation of authority:

The total nominal amount of ordinary shares that may be issued by virtue of this authority may not exceed €9 million;

This limit may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital;

The total nominal amount of debt securities of the Company that may be issued by virtue of this authority may not exceed €100 million.

The limits set above are independent of all other limits set by other resolutions of this general meeting.

- 4) If the Board of Directors makes use of this authority in the case of issues referred to above in point 1):
- a) Decide that the issue or issues of ordinary shares or securities giving access to the capital shall be reserved in priority for shareholders that may apply for shares on the basis of irrevocable entitlement (à titre irréductible);

- b) Decide that if applications for new shares on the basis of irrevocable entitlement, and as the case may be, for excess shares on a non-preferential basis (à titre réductible), should fail to account for the entire issue set forth in 1), the Board of Directors may have recourse to the following options:
- limit the amount of the issue to the amount of applications received, as applicable, within the limits provided for by regulation,
- freely allocate all or part of the securities not taken up;
- offer all or part of the securities not taken up to the public.
- 5) Decide that the issues of equity warrants of the Company may be carried out by a subscription offer but also by the award of bonus shares to owners of existing shares, it being specified that the Board of Directors shall be entitled to decide that the allotment rights forming fractional amounts shall not be negotiable and that the shares corresponding thereto will be sold.
- 6) Decide that the Board of Directors will be vested with, within the limits set forth above, all powers necessary notably to set the terms and conditions of the issue or issues and set the issue price, as appropriate, record the completion of the resulting capital increases, amend the bylaws in consequence, charge at its sole discretion the costs of the capital increase to the corresponding share premium and appropriate therefrom all amounts required to ensure that the legal reserve represents one tenth of the new share capital after each increase, and in general, take all actions required.
- 7) Duly note that this delegation of authority supersedes and cancels, for the unused portion, as applicable, any prior authorization having the same purpose.

Thirteenth resolution

Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities (of the Company or a Group company), and/or securities giving access to ordinary shares (by the Company or a Group company), canceling shareholders' preferential subscription rights by a public offering (with the exception of offers covered by 1 of article L.411-2 of the French financial and monetary code) and/or consideration for security tendered in connection with a public exchange offer.

The shareholders, having considered the Board of Directors' report and the auditors' special report, in accordance with the provisions of the French commercial code and particular, articles L. 225-129-2, L. 225-136, L. 225-148 and L. 228-92:

Grant the Board of Directors authority to proceed with the issue through one or more installments in amounts and at such times it chooses, in France and/or in other countries, through a public offering with the exception of offers covered by 1 of article L.411-2 of the French financial and monetary code, either in euros or in another currency, or in any other monetary unit established by reference to several currencies, of:

- ordinary shares;
- and/or ordinary shares granting entitlement to the allocation of other ordinary shares or debt securities;
- and/or securities giving access to ordinary shares to be issued.

The securities may be issued for payment of securities tendered to the Company in connection with public exchange offers for securities in accordance with the provisions of article L. 225-148 of the French Commercial Code.

In accordance with article L. 228-93 of the French commercial code, securities to be issued may give access to ordinary shares to be issued by any company which directly or indirectly holds more than half of its capital or a company in which it directly or indirectly holds more than half of its capital.

2) Set the duration for this authorization provided for under this resolution at twenty-six months from the date of this Meeting.

3) The total nominal amount of ordinary shares that may be issued by virtue of this authority may not exceed €9.000.000;

This limit may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital;

This amount is included within the maximum nominal amount of ordinary shares able to be issued set in the 19th resolution.

The total nominal amount of debt securities of the Company that may be issued by virtue of this delegation of authority may not exceed €50,000,000, it being specified that this limit is independent of all other limits set by other resolutions of this general meeting.

- 4) Decide to cancel the shareholders' preferential right to subscribe for ordinary shares and securities giving access to the capital of the company and/or debt securities covered by this resolution, while leaving the Board of Directors the possibility to grant shareholders a priority period, in accordance with the law.
- 5) Decide that the amount reverting, or that should revert, to the company for each of the ordinary shares issued under this delegation of authority, after taking into account, in the case of the issue of new equity warrants, the issue price of these warrants, shall be determined in accordance with law and regulations applicable on the date the Board of Directors implements this delegation of authority;
- 6) Decide, in the case of issuance of shares destined to be used in payment of securities tendered to the Company in connection with public exchange offers for securities in accordance with the provisions of article L. 225-148 of the French commercial code and within the limits set forth above, that the Board of Directors shall be vested with all necessary powers to draw up the list of securities to be tendered in the exchange, set the terms of the issue, the share exchange ratio, as well as, when applicable the balance to be paid in cash, and determine the procedures for the issue.
- 7) Decide that if applications for new shares should fail to account for the entire issue set forth in 1/, the Board of Directors may have recourse to the following options:
- limit the amount of the issue to the amount of applications received, as applicable, within the limits provided for by regulation,
- freely allocate all or part of the securities not taken up;
- 8) Decide that the Board of Directors will be vested with, within the limits set forth above, all powers necessary notably to set the terms and conditions of the issue or issues, as appropriate, record the completion of the resulting capital increases, amend the bylaws in consequence, charge at its sole discretion the costs of the capital increase to the corresponding share premium and appropriate therefrom all amounts required to ensure that the legal reserve represents one tenth of the new share capital after each increase, and in general, take all actions required.
- 9) Duly note that this delegation of authority supersedes and cancels, for the unused portion, as applicable, any prior authorization having the same purpose.

Fourteenth resolution

Delegation of authority to be granted to the Board of Directors to issue ordinary shares giving access to, as applicable, ordinary shares or entitlement to the allotment of debt securities (of the Company or a Group company), and/or securities giving access to ordinary shares (by the Company or a Group company), canceling shareholders' preferential subscription rights by a public offering provided for by 1° of article L.411-2 of the French monetary and financial code

The shareholders, having considered the Board of Directors' report and the Auditors' special report, in accordance with the provisions of the French commercial code and particular, articles L. 225-129-2, L. 225-136 and L. 228-92:

- 1) Grant the Board of Directors authority to proceed with the issue through one or more installments in amounts and at such times it chooses, in France and/or in other countries, through a public offering covered by article L.411-2 1 of the French Monetary and Financial Code, either in euros or in another currency, or in any other monetary unit established by reference to several currencies:
- ordinary shares:
- and/or ordinary shares granting entitlement to the allocation of other ordinary shares or debt securities;
- and/or securities giving access to ordinary shares to be issued.

In accordance with article L. 228-93 of the French commercial code, securities to be issued may give access to ordinary shares to be issued by any company which directly or indirectly holds more than half of its capital or a company in which it directly or indirectly holds more than half of its capital.

- 2) Set the duration for this authorization provided for under this resolution at twenty-six months from the date of this Meeting.
- 3) The total nominal amount of ordinary shares that may be issued under this resolution may not exceed €9,000,000, and shall be furthermore capped at 20 % of the share capital per year.

This limit may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital;

This amount is included within the maximum nominal amount of ordinary shares able to be issued set in the 19th resolution.

The total nominal amount of debt securities of the company that may be issued by virtue of this authority may not exceed €15,000,000, it being specified that this ceiling is independent from other ceilings provided for by other resolutions of this Meeting.

- 4) Decide to cancel shareholders' preemptive right to subscribe for ordinary shares and securities giving access to the capital of the company and/or debt securities covered by this resolution;
- 5) Decide that the amount reverting, or that should revert, to the company for each of the ordinary shares issued under this delegation of authority, after taking into account, in the case of the issue of new equity warrants, the issue price of these warrants, shall be determined in accordance with law and regulations applicable on the date the Board of Directors implements this delegation of authority;
- 6) Decide that if applications for new shares should fail to account for the entire issue set forth in 1/, the Board of Directors may have recourse to the following options:
- limit the amount of the issue to the amount of applications received, as applicable, within the limits provided for by regulation,
- freely allocate all or part of the securities not taken up;
- 7) Decide that the Board of Directors will be vested with, within the limits set forth above, all powers necessary notably to set the terms and conditions of the issue or issues, as appropriate, record the completion of the resulting capital increases, amend the bylaws in consequence, charge at its sole discretion the costs of the capital increase to the corresponding share premium and appropriate therefrom all amounts required to ensure that the legal reserve represents one tenth of the new share capital after each increase, and in general, take all actions required.
- 8) Duly note that this delegation of authority supersedes and cancels, for the unused portion, as applicable, any prior authorization having the same purpose.

Fifteenth resolution

Authorization, in the case of an issue entailing the cancellation of the preferential subscription right, to set, within the limit of 10 % of the share capital per year, the issue price according to the conditions set by the general meeting

The shareholders, having considered the Board of Directors' report and the auditors' report in accordance with the provisions of article L. 225-136-1, paragraph 2 of the French commercial code, authorize the Board deciding to issue ordinary shares or securities giving access to share capital, in accordance with the thirteenth and fourteenth resolutions, subject to the provisions of article L. 225-136 1° subsection 1 of the French commercial code, to derogate within the limit of 10% of the share capital from the conditions for setting the price provided for in the aforementioned resolutions and set the issue price for equity equivalent securities to be issued as follows:

The share price for equity equivalent securities to be issued immediately or in the future, may not be less, at the Board of Directors' choice than:

either the weighted average price of the Company's share on the day preceding the beginning of the offer, minus, as applicable, a discount of up to 20 %,

or the average trading price for five consecutive days selected from within a period of the thirty trading days preceding the beginning of the offer, minus a possible discount of up to 20 %

Sixteenth resolution

Authorization to increase the amount of issues

The shareholders, after considering the Board of Directors' report, resolve that for each issue of ordinary shares or securities giving access to the capital decided in application of the twelfth to the fourteenth resolution, the number of shares able to be issued may be increased in accordance with the provisions of articles L. 225-135-1 and R. 225-118 of the French commercial code and within the limits set by the general meeting.

Seventeenth resolution

Delegation of authority to the Board of Directors to proceed with a capital increase by issuing ordinary shares and/or securities giving access to the share capital within the limit of 10% of the capital as consideration for in-kind contributions of securities giving access to the capital

The shareholders, having considered the reports of the Board of Directors and the Auditors, and in accordance with articles L. 225-147 and L. 228-92 of the French commercial code:

- 1) Authorize the Board of Directors, pursuant to the equity auditor's report, to issue ordinary shares or securities giving access to ordinary shares as consideration for contributions in kind granted to the company and consisting of equity securities or securities giving access to the capital when the provisions of article L. 225-148 of the French commercial code are not applicable.
- 2) Set the duration for this authorization provided for under this resolution at twenty-six months from the date of this Meeting.
- 3) Decide that the total nominal amount of ordinary shares that may be issued by virtue of this authorization may not exceed 10 % of the share capital on the date of this meeting, without taking into account the nominal amount of the capital increase required, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the Company's capital.

This amount is included within the maximum nominal amount of ordinary shares able to be issued set in the 19th resolution.

- 4) All powers are granted to the Board of Directors for the purpose of approving the valuation of in-kind contributions, deciding on the capital increase resulting therefrom and recording its completion, charging as applicable to additional paid-in capital all expenses and duties incurred in connection with the capital increase, appropriating from these amounts the funds necessary so that the legal reserve equals one tenth the new capital after each issue, making the corresponding changes to the bylaws and in general doing all else that is required in such matters.
- 5) Duly note that this delegation of authority supersedes and cancels, for the unused portion, as applicable, any prior authorization having the same purpose.

Eighteenth resolution

Delegation of authority to the Board of Directors to proceed with a capital increase through the issuance of shares and/or securities giving access to the share capital suspending shareholders' preferential rights in favor of employees participating in a company savings plan pursuant to the provisions of Articles L. 3332-18 et seq. of the French labor code.

The shareholders, after reviewing the Board of Directors' report and the Auditors' special report, ruling in accordance with the provisions of Articles L.225-129-6, L.225-138-1 and L.228-92 of the French commercial code and Article L.3332-18 et seq. of the French labor code:

- 1)Delegate their authority to the Board of Directors, for the purpose, if it deems opportune, on the basis of its decision alone, of increasing the share capital, at once or in installments, by issuing ordinary shares or securities giving access to the Company's capital to be issued in favor of participants in one or more company or group employee stock ownership plans established by the company and/or French or foreign companies affiliated with it in accordance with the provisions of article L. 225-180 of the French commercial code and article L. 3344-1 of the French labor code.
- 2) Cancel in favor of these persons the preferential subscription rights to shares that may be issued under this delegation of authority.
- 3) Set the period of validity of this delegation of authority at twenty-six months from the date of this meeting.
- 4) Limit the maximum nominal amount of the capital increase(s) that may be carried out under this authorization to 2% of the share capital on the date of the Board of Directors' decision to proceed with this capital increase, whereby this amount is included within the maximum nominal amount of ordinary shares able to be issued set in the 19th resolution. This amount may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital.

- 5) Decide that the price of the shares to be issued pursuant to subsection 1) of this authorization may not be more than 30 % or 40 % below, when the lock-up period provided for under the plan in accordance with Articles L .3332-25 and L. 3332-26 of the French labor code is greater than or equal to ten years, the average opening price for the twenty trading sessions preceding the date of the Board of Directors' decision setting the opening date of the subscription nor greater than this average.
- 6) Decide, in application of the provisions of Article L.3332-21 of the French labor code, that the Board of Directors may provide for grants without consideration to beneficiaries defined above in the first paragraph, of shares to be issued or already issued or other securities giving access to the Company's share capital to be issued or already issued, with respect to (i) contributions that may be paid in accordance with procedures for company or group stock ownership plans and/or (ii), as applicable, the discount and may decide in the case of the issuance of new shares and/or the contribution, to proceed with the capitalization of the reserves, earnings or additional paid-in capital for the payment of said shares.
- 7) Duly note that this delegation of authority supersedes and cancels, for the unused portion, as applicable, any prior authorization having the same purpose.

The Board of Directors may or may not implement this delegation of authority, take all necessary measures and proceed with all necessary formalities:

Nineteenth resolution

Aggregate limit of ceilings of delegations of authority provided for by the thirteenth, fourteenth, seventeenth and eighteenth resolutions of this General Meeting

The shareholders, after considering the Board of Directors' report, decide to set at:

- 10 % of the amount of share capital on the issue date, the total number of shares that may be issued, immediately or in the future, provided for in the thirteenth, fourteenth, seventeenth and eighteenth resolution of this Meeting, it being specified that this amount may be increased, as necessary, by the nominal amount of the capital increase necessary to preserve, in accordance with the law, and, as applicable, contractual provisions providing for other methods for preserving rights, the rights of holders of rights or securities giving access to the company's capital.

Twentieth resolution

Modification of article 14 of the bylaws to provide for recourse to written consultation by the directors

The shareholders, after considering the Board of Directors' report, decide in accordance with the option provided for by article L. 225-37 of the French commercial code as amended by Law No. 2019-744 of July 19, 2019, to provide for the possibility of members of the Board of Directors to make decisions relating to its own functions restrictively limited by regulation by means of a written consultation, and modifying consequence article 14 of the bylaws as follows:

At the end of article 14 of the bylaws the following paragraph is inserted, with the remainder of the article unchanged:

"The Board of Directors may also make decisions by means of a written consultation of the directors under the conditions provided for by law."

Twenty-first resolution

Modification of article 14 of the bylaws concerning the use of videoconferencing or telecommunications technology

The shareholders, after having reviewed the report of the Board of Directors, decide:

- to expressly provide, in addition to the possibility of participating in certain meetings of the Board by means of videoconferencing, the possibility to also attend through telecommunications technologies in accordance with provisions of article L. 225-37 of the French commercial code;
- to modify the list of decisions that may not be adopted by the Board at meetings conducted by means of videoconferencing or telecommunications technologies in order to include only those subject to legal exclusions.
- to modify in consequence as follows the fourth subsection of article 14 of the bylaws, with the remainder of the article unchanged:

"The Board charter may provide that directors who attend the Board meeting through videoconferencing or telecommunications means in accordance with laws and regulations, are deemed present for determining the quorum and majority.

This provision is not applicable with respect to adopting decisions concerning the closing of the annual and consolidated accounts and the preparation of the management report for the Company and/or Group."

Twenty-second resolution

Modification of article 16 of the bylaws concerning the procedures for exercising Executive Management

The shareholders, after considering the Board of Directors' report, decide to cancel the restriction linked to the duration of the decision made by the Board concerning the procedures for exercising Executive Management functions and to cancel in consequence the last sentence of the third subsection of article 16 of the bylaws, with the remainder of the article unchanged.

Twenty-third resolution

Harmonization of the bylaws

The shareholders, after having considered the report of the Board of Directors, decide:

- 1) Concerning the procedure for identifying owners of bearer shares:
- to harmonize article 9 of the bylaws with the provisions of articles L. 228-2 et seq. of the French commercial code as amended by Law No. 2019-486 of May 22 2019 concerning the growth and transformation of companies that modifies the procedure for identifying shareholders;
- to modify in consequence as follows the fifth subsection of article 9 of the bylaws, with the remainder of the article unchanged:

"The Company may request at any time, in accordance with applicable laws and regulations, the disclosure of information regarding the identity of holders of securities issued by it which give immediate or future rights to vote in shareholders meetings."

- 2) Concerning the wording relating to ordinary agreements entered into under normal conditions:
- to harmonize article 18 of the bylaws concerning ordinary agreements entered into under normal conditions by replacing the reference to article L. 225-38 of the French commercial code by a reference to article L. 225-39 of said code;
- to modify in consequence as follows the fourth subsection of article 18 of the bylaws, with the remainder of the article unchanged:

In accordance with the provisions of article L.225-39 of the French commercial code, the above provisions are not applicable to agreements concerning current operations entered into under normal conditions nor to agreements entered into between two companies, one of which holds, directly or indirectly, all of the share capital of the other, if applicable, less the minimum number of shares required to satisfy the requirements of article 1832 of the French civil code, or articles L.225-1 and L.226-1 of the French commercial code."

- 3) Concerning the textual reference to the signature of electronic forms:
- to harmonize article 19 of the bylaws with the provisions of Ordinance No. 2016-131 of February 10, 2016 on the reform of contract law, the general regime and proof of obligations resulting in a re-codification of the provisions of the French Civil Code relating to the electronic signature;
- to modify in consequence as follows the second sentence of the fourth subsection of the paragraph "Access to and Representation at General Meetings" of article 19 of the bylaws:

"Electronic forms may be completed and signed directly in accordance with the first line of the second subsection of Article 1367 of the French Civil Code (Code Civil), notably by means of an identifier and password."

- 4) Concerning the invalidation of the proxy or vote expressed before the record date:
- to harmonize article 19 with the provisions of article L. 225-85 of the French commercial code as amended by Decree No. 2014-1466 of December 8, 2014, amending the date and procedures for establishing the list of persons authorized to participate in meetings of shareholders and bondholders of commercial companies;
- to modify in consequence as follows the third sentence of the fourth subsection of the paragraph "Access to and Representation at General Meetings" of article 19 of the bylaws, with the remainder of the article unchanged:

"The proxy or voting forms completed electronically prior to the meeting, as well as the acknowledgment of receipt that will be given in reply, will be considered as irrevocable written proof and binding on all parties. Notwithstanding the foregoing, in the transfer of title of the shares occurring before the second business day preceding the Shareholders' Meeting at midnight (Paris time), the company shall invalidate or modify accordingly, as the case may be, the vote by proxy or voting form before this date and time."

Twenty-fourth resolution

Textual references applicable in the case of a change in codification

The general meeting duly notes that the textual references mentioned in all resolutions of this Meeting make reference to the legal and regulatory provisions applicable on their date of establishment and that in the event of a modification of the codification thereof in connection with the authorization granted by the Law No. 2019-486 of May 22, 2019 to the government, the textual references corresponding to this new qualification will replace the former.

Twenty-fifth resolution

Powers for formalities

The General Meeting grants all powers to the holder of an original, a short-form certificate or a copy of these minutes to carry out all the publication, filing and other formalities that may be required by law.

Statutory auditors' report

Statutory Auditors' report on the annual financial statements

To Interparfums' Annual General Meeting:

Opinion

In accordance with the terms of our engagement as auditors by your Annual General Meeting, we have audited the accompanying annual financial statements of Interpartums for the year ended December 31, 2019. These financial statements were adopted by the Board of Directors on 2 March 2020 based on information available at that date within an evolving environment for the health crisis linked to Covid-19.

In our opinion, the financial statements give a true and fair view of the assets and liabilities and of the financial position of the Company as at December 31, 2018 and of the results of its operations for the year then ended in accordance with French accounting principles.

The audit opinion expressed above is consistent with our report to the Audit Committee

Basis for opinion

Audit framework

We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the "Statutory Auditors' Responsibilities for the Audit of the Annual Financial Statements" section of our report.

Independence

We conducted our audit in compliance with independence rules applicable to us, for the period from January 1, 2018 to the issue date of our report and in particular we did not provide any prohibited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014 or in the French Code of ethics for Statutory Auditors.

Justification of assessments - Key audit matters

In accordance with the requirements of articles L.823-9 and R.823-7 of the French commercial code ("code de commerce") relating to the justification of our assessments, we bring your attention to the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in the audit of the annual financial statements of the period, as well as our responses to those risks

These matters were addressed in the context of our audit of the consolidated financial statements as a whole, adopted under the conditions previously described, and in forming our opinion thereon, and we do not provide a separate opinion on specific elements, accounts or items of the consolidated financial statements.

Measurement of intangible assets

· Identified risk

At December 31, 2019, the Company's intangible assets were valued at €114 million out of total assets of €561 million. These intangible assets represent expenses incurred in connection with the acquisition of licenses or brands.

Licenses and upfront license fees are tested for impairment at least once a year according to the discounted cash flow method based on estimated future cash flows expected to arise from the continuing use of these assets. Proprietary brands are remeasured annually according to the same method.

A provision for impairment is recorded if this value is lower than the carrying value.

Notes 1.4 and 2.1 to the annual financial statements describe the procedures for conducting these impairment tests.

We have considered that the measurement of these intangible assets to be a key audit matter due to their material importance in the Company's financial statements and because the determination of recoverable value is in most cases based on estimations for discounted future cash flows requiring assumptions, estimates or assessments of Company management.

• Responses as part of our audit

We have reviewed the work performed by the Company and the procedures used for conducting impairment tests. We paid particular attention to the brands and license agreements whose carrying value was close to the estimated recoverable value..

We also assessed the main estimates used by management to produce the cash flow forecasts based on the information available.

We assessed the relevance of the discount rates adopted with the assistance of our internal financial appraisal specialists and conducted sensitivity tests.

Specific procedures

We have also performed the other specific procedures required by French law and regulations, in accordance with professional practice standards applicable in France.

• Information given in the management report and other documents addressed to shareholders with respect to the financial position and the financial statements

We have no matters to report regarding the fair presentation and consistency with the financial statements of the information given in the Management Report of the Board of Directors adopted March 2, 2020 and the other documents addressed to the shareholders in respect of the financial position and the annual financial statements. With respect to events having occurred and circumstances known after the closing date of the accounts with respect to the impacts of the Covid-19 health crisis, management has indicated that it will provide information to the General Meeting for the purpose of approving the financial statements

We attest to the fair presentation and the consistency with the financial statements of the information relating to payment deadlines mentioned in article D. 441-4 of the French commercial code.

Report on corporate governance

We certify that the Board of Directors' report on corporate governance includes the information required by articles L. 225-37-3 and L. 225-37-4 of the French commercial code.

Concerning the information given in accordance with the requirements of article L.225-37-3 of the French commercial code relating to compensation and benefits paid or granted to corporate officers and any other commitments made in their favor, we have verified their consistency with the financial statements, or with the underlying information used to prepare these financial statements and, where applicable, with the information obtained by your company from companies controlled by it and included in the consolidation scope. Based on this work, we attest the accuracy and fair presentation of this information.

Concerning the information relating to items that your Company considers may have an impact in the case of a takeover bid or a public exchange offer provided in application of the provisions of L. 225-37-5 of the French commercial code, we have verified their consistency with relevant source documents. Based on this work, we have no matters to report in connection with the information given.

· Other information

In accordance with French law, we have verified that the required information concerning the identity of the shareholders and holders of the voting rights has been properly disclosed in the management report.

Report on other legal and regulatory requirements

· Appointment of statutory auditors

We were appointed as Statutory Auditors of Interparfums by the General Meeting of December 1, 2004 for Mazars and of May 19, 1995 for SFECO & Fiducia Audit.

As at December 31, 2019, Mazars was in its 16^{th} period of total uninterrupted engagement and SFECO & Fiducia Audit in its 25^{th} period.

Responsibilities of management and those charged with governance for the annual financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with French accounting principles, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the annual financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected to liquidate the Company or to cease its operations.

The Audit Committee is responsible for monitoring the financial reporting process and the effectiveness of internal control and risk management systems and, where applicable, its internal audit, regarding the accounting and financial reporting procedures.

The annual financial statements have been approved by the Board of Directors.

Statutory auditors' responsibilities for the audit of the annual financial statements

· Objective and audit approach

Our role is to issue a report on the annual financial statements. Our objectives are to obtain reasonable assurance about whether the annual financial statements as a whole are free from material misstatement. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As specified by article L.823-10-1 of the French commercial code ("code de commerce"), the scope of our statutory audit does not include assurance on the future viability of the Company or the quality with which Company's management has conducted or will conduct the affairs of the entity.

As part of an audit in accordance with professional standards applicable in France, we exercise our professional judgment throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial statements, whether due to
 fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence
 that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material
 misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve
 collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the annual financial statements;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If we conclude that a material uncertainty exists, we draw attention in our audit report to the related disclosures in the annual financial statements or, if such disclosures are not provided or inadequate, we issue a qualified opinion or no opinion at all;
- Evaluate the overall presentation of the annual financial statements and whether the annual financial statements represent the underlying transactions and events in a manner that achieves fair presentation;

• Report to the Audit Committee

We submit a report to the Audit Committee which includes in particular a description of the scope of the audit and the audit program implemented, as well as significant audit findings. We also bring to its attention, if need be, any significant deficiencies in internal control regarding the accounting and financial reporting procedures that we have identified.

Our report to the Audit Committee includes information about the risks of material misstatement that, in our professional judgment, were of most significance in the audit of the annual financial statements of the current period and which are therefore the key audit matters. We describe these matters in the audit report.

We also provide the Audit Committee with the declaration referred to in Article 6 of Regulation (EU) N° 537/2014, confirming our independence within the meaning of the rules applicable in France as defined in particular by articles L.822-10 to L.822-14 of the French commercial code ("code de commerce") and in the French code of ethics for statutory auditors.

Where appropriate, we discuss with the Audit Committee the risks that may reasonably be thought to bear on our independence, and where applicable, the related safeguards.

Courbevoie and Paris, April 27, 2020

The Statutory Auditors

French original signed by:

Mazars Guillaume Wadoux

SFECO& Fiducia Audit Gilbert Berdugo

Statutory Auditors' report on the consolidated financial statements

To Interparfums' Annual General Meeting:

Opinion

In accordance with the terms of our engagement as auditors by your Annual General Meeting, we have audited the accompanying consolidated financial statements of Interpartums for the year ended December 31, 2019. These financial statements were adopted by the Board of Directors on 2 March 2020 based on information available at that date within an evolving environment for the health crisis linked to Covid-19. In our opinion, the consolidated financial statements give a true and fair view of the results of the operations of the Group for the year then ended and of its financial position and its assets and liabilities as at December 31, 2018 in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

The audit opinion expressed above is consistent with our report to the Audit Committee

Basis for opinion

Audit framework

We conducted our audit in accordance with professional standards applicable in France. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the "Statutory Auditors' Responsibilities for the Audit of the Consolidated Financial Statements" section of our report.

• Independence

We conducted our audit in compliance with independence rules applicable to us, for the period from January 1, 2018 to the issue date of our report and in particular we did not provide any prohibited non-audit services referred to in Article 5(1) of Regulation (EU) No 537/2014 or in the French Code of ethics for Statutory Auditors.

Observation

Without qualifying the opinion expressed above, we draw your attention as an emphasis of matter to note 1.2.1 and 3.3 to the consolidated financial statements concerning the application as from January 1, 2019 of IFRS 16 "Leases" and IFRIC 23 interpretation on "Uncertainty over income tax treatments".

Justification of assessments - Key audit matters

In accordance with the requirements of articles L. 823-9 and R. 823-7 of the French commercial code ("code de commerce") relating to the justification of our assessments, we bring your attention to the key audit matters relating to risks of material misstatement that, in our professional judgment, were of most significance in the audit of the consolidated financial statements of the current period, as well as our responses to those risks.

These matters were addressed in the context of our audit of the annual financial statements as a whole, adopted under the conditions previously described, and in forming our opinion thereon, and we do not provide a separate opinion on specific elements, accounts or items of the consolidated financial statements.

Measurement of trademarks and other intangible assets

Identified risk

At December 31, 2019, brands and other intangible assets were valued at €155 million out of total assets of €601 million. These intangible assets represent mainly expenditures relating to the acquisition of licenses or brands

These intangible assets are tested for impairment when there exists evidence of a loss in value for the licenses and upfront license fees at least once a year for own brands. Recoverable value is determined as follows:

- for licenses and upfront license fees, according to the discounted cash flow method defined as the present value of estimated future cash flows expected to arise from the continuing use of these assets calculated according to their estimated or actual length,
- for own brands, as the higher of fair value less costs to sell and its value in use on the basis of the present value of estimated future cash flows derived from multi-year budgets established for five-year periods discounted to infinity.

A provision for impairment is recorded when the recoverable value of the assets is lower than the carrying value. Notes 1.7 and 3.1 to the consolidated financial statements describe the procedures for conducting impairment tests.

We have considered that the measurement of these intangible assets to be a key audit matter due to their material importance in the Company's financial statements and because the determination of recoverable value is in most cases based on estimations for discounted future cash flows requiring assumptions, estimates or assessments of company management.

• Responses as part of our audit

We have reviewed the work performed by the Company and the procedures used for conducting impairment tests. We paid particular attention to the brands and license agreements whose carrying value was close to the estimated recoverable value..

We also assessed the main estimates used by management to produce the cash flow forecasts based on the information available.

We assessed the relevance of the discount rates adopted with the assistance of our internal financial appraisal specialists and conducted sensitivity tests.

Finally, we reviewed the mathematical calculations performed by the Company and verified the appropriateness of the disclosures in the notes to the consolidated financial statements.

Specific procedures

As required by French law and regulations, we also performed the specific verifications in accordance with professional standards applicable in France of the information provided on the group presented in the Board of Directors' management report adopted March 2, 2020. With respect to events having occurred and circumstances known after the closing date of the accounts with respect to the impacts of the Covid-19 health crisis, management has indicated that it will provide information to the General Meeting for the purpose of approving the financial statements.

We have nothing to report with respect to the fair presentation of such information and its consistency with the consolidated financial statements.

Report on other legal and regulatory requirements

• Appointment of statutory auditors

We were appointed as Statutory Auditors of Interparfums by the General Meeting of December 1, 2004 for Mazars and of May 19, 1995 for SFECO & Fiducia Audit.

As at December 31, 2019, Mazars was in its 16^{th} period of total uninterrupted engagement and SFECO & Fiducia Audit in its 25^{th} period.

Responsibilities of management and those charged with governance for the consolidated financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless it is expected to liquidate the Company or to cease its operations. The Audit Committee is responsible for monitoring the financial reporting process and the effectiveness of internal control and risk management systems and, where applicable, its internal audit, regarding the accounting and financial reporting procedures. The consolidated financial statements have been approved by the Board of Directors.

Statutory auditors' responsibilities for the audit of the consolidated financial statements

· Objective and audit approach

Our role is to issue a report on the consolidated financial statements. Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with professional standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements. As specified by article L.823-10-1 of the French commercial code ("code de commerce"), the scope of our statutory audit does not include assurance on the future viability of the Company or the quality with which Company's management has conducted or will conduct the affairs of the entity.

As part of an audit in accordance with professional standards applicable in France, we exercise our professional judgment throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a
 material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve
 collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control:
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management in the consolidated financial statements;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. Our conclusions are based on the audit evidence obtained up to the date of our audit report. However, future events or conditions may cause the Company to cease to continue as a going concern. If we conclude that a material uncertainty exists, we draw attention in our audit report to the related disclosures in the consolidated financial statements or, if such disclosures are not provided or inadequate, we modify our opinion;
- Evaluate the overall presentation of the consolidated financial statements and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation;
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities included in the consolidation scope to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the consolidated financial statements. We remain solely responsible for our audit opinion.

• Report to the Audit Committee

We submit a report to the Audit Committee which includes in particular a description of the scope of the audit and the audit program implemented, as well as significant audit findings. We also bring to its attention, if need be, any significant deficiencies in internal control regarding the accounting and financial reporting procedures that we have identified. Our report to the Audit Committee includes information about the risks of material misstatement that, in our professional judgment, were of most significance in the

audit of the consolidated financial statements of the current period and which are therefore the key audit matters. We describe these matters in the audit report.

We also provide the Audit Committee with the declaration referred to in Article 6 of Regulation (EU) N° 537/2014, confirming our independence within the meaning of the rules applicable in France as defined in particular by articles L. 822-10 to L. 822-14 of the French commercial code ("code de commerce") and in the French code of ethics for statutory auditors. Where appropriate, we discuss with the Audit Committee the risks that may reasonably be thought to bear on our independence, and where applicable, the related safeguards.

Courbevoie and Paris, April 27, 2020

The Statutory Auditors

French original signed by:

Mazars Guillaume Wadoux

SFECO& Fiducia Audit Gilbert Berdugo

Statutory Auditors' special report on regulated agreements

To Interparfums' Annual General Meeting:

In our capacity as Statutory Auditors of your Company, we hereby report on regulated agreements.

The terms of our engagement require us to communicate to you, based on information provided to us, the principal terms and conditions of those agreements brought to our attention or which we may have discovered during the course of our audit, as well as the reasons justifying that such agreements are in the Company's interest, without expressing an opinion on their usefulness and appropriateness or identifying such other agreements, if any. It is your responsibility, pursuant to article R. 225-31 of the French commercial code to assess the interest involved in respect of the conclusion of these agreements with a view to their approval.

Our role is also to provide you with the information stipulated in Article R. 225-31 of the French commercial code on agreements previously approved by the General Meeting, if any, in force during the period.

We conducted the procedures we deemed necessary in accordance with the professional guidelines of the French National Institute of Statutory Auditors (Compagnie Nationale des Commissaires aux Comptes) relating to this engagement.

Agreements submitted for approval to the General Meeting

We hereby inform you that we were not notified of any agreement authorized and concluded during the past financial year to be submitted to the Annual General Meeting for approval in accordance with the provisions of Article L.226-38 of the French commercial code

Agreements already approved by the General Meeting

We inform you that we have not been advised of any agreement or commitment already approved by the General Meeting remaining in force in the period under review.

Courbevoie and Paris, April 27, 2020

The Statutory Auditors

French original signed by:

Mazars Guillaume Wadoux

SFECO& Fiducia Audit Gilbert Berdugo



Request to be sent statutory documents and information

Combined Ordinary and Extraordinary General Meeting of June 24, 2020.

Covered under R.225-83 of the French commercial code

To be returned to Interparfums by email:

relationsactionnaires@interparfums.fr

or by regular mail to: Shareholder Relations, Ms. Karine Marty,

4 rond-point des Champs-Élysées, 75008 Paris

Ms. o	Mr. o	Company o	
Name (or c	ompany name):	
First name:.			
Complete	address:		
No			. Street:
Postal code	∋:		. City:
Email:			
Owner of:			. registered shares
And/or of:			. bearer shares
Registered	with (1):		
(1) Indicate t	he bank, financio	ıl establishment or b	prokerage firm maintaining the securities account.
commercic	al code, cor	ntained in the	nformation provided for under article R.225-83 of the French 2019 Universal Registration Document, available at s/Regulated information:
Place:			.Date:2020
Signature:			

NB: In accordance with the provisions of article R.225-88, subsection 3 of the French commercial code, as from the date of this notice of meeting until the fifth day (inclusive) before the meeting, any shareholder in possession of registered shares may ask to receive a copy of the documents and information covered by articles R.225-81 and R.225-83 of the French commercial code, in connection with each of the subsequent General Meetings of the shareholders. In this case, this must be indicated by the shareholder in this request. In addition to the information provided in this document, the information provided for in R.225-81 and R.225-83 is contained in the Registration Document available at www.interparfums.fr in the section "Investors/Regulated information.